<?xml version="1.0"?>
<rdf:RDF xmlns="http://ontofox.hegroup.org/mtun9fm3.owl#"
     xml:base="http://ontofox.hegroup.org/mtun9fm3.owl"
     xmlns:obo="http://purl.obolibrary.org/obo/"
     xmlns:owl="http://www.w3.org/2002/07/owl#"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:xml="http://www.w3.org/XML/1998/namespace"
     xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
     xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
     xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#"
     xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#">
    <owl:Ontology rdf:about="http://ontofox.hegroup.org/reuse.owl"/>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Annotation properties
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://purl.obolibrary.org/obo/IAO_0000111 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000111"/>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000115 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000115">
        <obo:IAO_0000115>A property representing the English language definitions of what NCI means by the concept. They may also include information about the definition&apos;s source and attribution in a form that can easily be interpreted by software.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>DEFINITION</oboInOwl:hasExactSynonym>
        <rdfs:label>definition</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000118 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000118"/>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000412 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000412">
        <rdfs:label xml:lang="en">imported from</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_A24 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_A24">
        <obo:IAO_0000115>An association that indicates a PCDC AML concept is a Permissible Value for a PCDC AML Variable concept.</obo:IAO_0000115>
        <obo:NCIT_NHC0>A24</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>Is_PCDC_AML_Permissible_Value_For_Variable</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Is_PCDC_AML_Permissible_Value_For_Variable</oboInOwl:hasExactSynonym>
        <rdfs:label>Is_PCDC_AML_Permissible_Value_For_Variable</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_A32 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_A32">
        <obo:IAO_0000115>An association that that connects a concept representing a GDC value to any associated GDC property concept(s).</obo:IAO_0000115>
        <obo:NCIT_NHC0>A32</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>Is_Value_For_GDC_Property</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Is_Value_For_GDC_Property</oboInOwl:hasExactSynonym>
        <rdfs:label>Is_Value_For_GDC_Property</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_A7 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_A7">
        <obo:IAO_0000115>An association that connects a drug or other agent to a clinically intended, molecular-scale target. The target value may be a gene, gene product, anatomic structure, cell, biological process, or other concept, where the effect of the agent on the target is thought to be of therapeutic, diagnostic, or other clinical relevance to a disease process. The effect is most often direct, as defined at a molecular scale, but may also be indirect and/or defined at a larger scale.</obo:IAO_0000115>
        <obo:NCIT_NHC0>A7</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>Has Target</obo:NCIT_P107>
        <obo:NCIT_P108>Has_Target</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Has_Target</oboInOwl:hasExactSynonym>
        <rdfs:label>Has_Target</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_NHC0 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_NHC0">
        <obo:IAO_0000115>A property representing a concept unique identifier within the NCI Enterprise Vocabulary Service&apos;s NCI Thesaurus.</obo:IAO_0000115>
        <obo:NCIT_NHC0>NHC0</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>code</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>code</oboInOwl:hasExactSynonym>
        <rdfs:label>code</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P106 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P106">
        <obo:IAO_0000115>A property that represents a description of the sort of thing or category to which a concept belongs in the context of the UMLS semantic network.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P106</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>Semantic Type</obo:NCIT_P107>
        <obo:NCIT_P108>Semantic_Type</obo:NCIT_P108>
        <obo:NCIT_P98>In general, applying semantic types aids in allowing users (or computer programs) to draw conclusions about concepts by virtue of the categories to which they have been assigned.  We use a set of semantic types developed for the UMLS Metathesaurus. There are currently 134 semantic types in the UMLS.</obo:NCIT_P98>
        <oboInOwl:hasExactSynonym>Semantic_Type</oboInOwl:hasExactSynonym>
        <rdfs:label>Semantic_Type</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P107 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P107">
        <obo:IAO_0000115>A property representing an alternative Preferred Name for use in some NCI systems.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P107</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>Display Name</obo:NCIT_P107>
        <obo:NCIT_P108>Display_Name</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Display Name</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Display_Name</oboInOwl:hasExactSynonym>
        <rdfs:label>Display_Name</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P108 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P108">
        <obo:IAO_0000115>A property representing the word or phrase that NCI uses by preference to refer to the concept.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P108</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>Preferred Name</obo:NCIT_P107>
        <obo:NCIT_P108>Preferred_Name</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Preferred Name</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Preferred Term</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Preferred_Name</oboInOwl:hasExactSynonym>
        <rdfs:label>Preferred_Name</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P171 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P171">
        <obo:IAO_0000115>A property used to provide a primary reference for descriptions of an NCI Thesaurus concept.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P171</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>PubMedID Primary Reference</obo:NCIT_P107>
        <obo:NCIT_P108>PubMedID_Primary_Reference</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>PubMedID_Primary_Reference</oboInOwl:hasExactSynonym>
        <rdfs:label>PubMedID_Primary_Reference</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P207 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P207">
        <obo:IAO_0000115>A property representing the concept unique identifier (CUI) assigned by the National Library of Medicine (NLM). If a concept in any NCI-maintained knowledgebase exists in the NLM Unified Medical Language System (UMLS), NCI includes the NLM CUI among the information we provide about the concept.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P207</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>UMLS CUI</obo:NCIT_P107>
        <obo:NCIT_P108>UMLS_CUI</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>UMLS_CUI</oboInOwl:hasExactSynonym>
        <rdfs:label>UMLS_CUI</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P208 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P208">
        <obo:IAO_0000115>A property representing the concept unique identifier (CUI) for those concepts that appear in NCI Metathesaurus but not in the National Library of Medicine Unified Medical Language System (NLM UMLS).</obo:IAO_0000115>
        <obo:NCIT_NHC0>P208</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>NCI Metathesaurus CUI</obo:NCIT_P107>
        <obo:NCIT_P108>NCI_META_CUI</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>NCI_META_CUI</oboInOwl:hasExactSynonym>
        <rdfs:label>NCI_META_CUI</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P210 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P210">
        <obo:IAO_0000115>A property representing the Chemical Abstracts Service number for a Chemical or Drug.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P210</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>CAS Registry Number</obo:NCIT_P107>
        <obo:NCIT_P108>CAS_Registry</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>CAS_Registry</oboInOwl:hasExactSynonym>
        <rdfs:label>CAS_Registry</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P319 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P319">
        <obo:IAO_0000115>A property representing the FDA Unique Ingredient Identifier, a key component of the federal drug information model.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P319</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>FDA UNII Code</obo:NCIT_P107>
        <obo:NCIT_P108>FDA_UNII_Code</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>FDA_UNII_Code</oboInOwl:hasExactSynonym>
        <rdfs:label>FDA_UNII_Code</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P322 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P322">
        <obo:IAO_0000115>A property is used to indicate when a non-EVS entity has contributed to, and has a stake in, a concept. This is used where such entities, within or outside NCI, have indicated the need to be able to track their own concepts. A single concept can have multiple instances of this property if multiple entities have such a defined stake.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P322</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>Contributing Source</obo:NCIT_P107>
        <obo:NCIT_P108>Contributing_Source</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Contributing_Source</oboInOwl:hasExactSynonym>
        <rdfs:label>Contributing_Source</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P325 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P325">
        <obo:IAO_0000115>A property representing the English language definition of a concept from a source other than NCI.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P325</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>[source] Definition</obo:NCIT_P107>
        <obo:NCIT_P108>ALT_DEFINITION</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>ALT_DEFINITION</oboInOwl:hasExactSynonym>
        <rdfs:label>ALT_DEFINITION</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P350 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P350">
        <obo:IAO_0000115>A property representing a concise expression about the atoms that constitute a particular chemical compound.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P350</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>Chemical Formula</obo:NCIT_P107>
        <obo:NCIT_P108>Chemical_Formula</obo:NCIT_P108>
        <obo:NCIT_P322>CRCH</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>Chemical Formula</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Chemical_Formula</oboInOwl:hasExactSynonym>
        <rdfs:label>Chemical_Formula</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P366 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P366">
        <obo:IAO_0000115>A property representing a retired unique concept identifier created and stored as Concept Name by legacy EVS software. Use of these values was long discouraged, but continued as late as 2009 when creation of new values ceased and Concept Name was retired. Legacy values are intended solely to help resolve and update earlier coding.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P366</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>Legacy Concept Name</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Legacy Concept Name</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Legacy_Concept_Name</oboInOwl:hasExactSynonym>
        <rdfs:label>Legacy Concept Name</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P368 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P368">
        <obo:IAO_0000115>A property representing that a concept in the &apos;Drug, Food, Chemical or Biomedical Material&apos; branch of the NCI thesaurus maps to a specific concept in the EBI Chemical Entities of Biological Interest (CHEBI) database.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P368</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>CHEBI_ID</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>CHEBI_ID</oboInOwl:hasExactSynonym>
        <rdfs:label>CHEBI_ID</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P375 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P375">
        <obo:IAO_0000115>A property representing that a term in another terminology has been mapped to a term in NCIt and describes the relationship between the mapped terms.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P375</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>Maps_To</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>Maps_To</oboInOwl:hasExactSynonym>
        <rdfs:label>Maps_To</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P399 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P399">
        <obo:IAO_0000115>A property representing the numerical CDR ID, which is the NCI Drug Dictionary identifier for a chemical or pharmaceutical agent.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P399</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P108>NCI_Drug_Dictionary_ID</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>NCI_Drug_Dictionary_ID</oboInOwl:hasExactSynonym>
        <rdfs:label>NCI_Drug_Dictionary_ID</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_P98 -->

    <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/NCIT_P98">
        <obo:IAO_0000115>A property representing notations made by NCI vocabulary curators. They are intended to provide supplemental, unstructured information to the user or additional insight about the concept.</obo:IAO_0000115>
        <obo:NCIT_NHC0>P98</obo:NCIT_NHC0>
        <obo:NCIT_P106>Conceptual Entity</obo:NCIT_P106>
        <obo:NCIT_P107>DesignNote</obo:NCIT_P107>
        <obo:NCIT_P108>DesignNote</obo:NCIT_P108>
        <oboInOwl:hasExactSynonym>DesignNote</oboInOwl:hasExactSynonym>
        <rdfs:label>DesignNote</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasExactSynonym -->

    <owl:AnnotationProperty rdf:about="http://www.geneontology.org/formats/oboInOwl#hasExactSynonym">
        <obo:IAO_0000115>A property representing a fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>FULL_SYN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Synonym with Source Data</oboInOwl:hasExactSynonym>
        <rdfs:label>has exact synonym</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#inSubset -->

    <owl:AnnotationProperty rdf:about="http://www.geneontology.org/formats/oboInOwl#inSubset">
        <obo:IAO_0000115>An association that connects the concept defining a particular terminology subset with concepts that belong to this subset.</obo:IAO_0000115>
        <oboInOwl:hasExactSynonym>Concept_In_Subset</oboInOwl:hasExactSynonym>
        <rdfs:label>in subset</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.w3.org/2000/01/rdf-schema#label -->

    <owl:AnnotationProperty rdf:about="http://www.w3.org/2000/01/rdf-schema#label">
        <rdfs:label>label</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Object Properties
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://purl.obolibrary.org/obo/BFO_0000051 -->

    <owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/BFO_0000051">
        <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#TransitiveProperty"/>
        <obo:IAO_0000111 xml:lang="en">has part</obo:IAO_0000111>
        <obo:IAO_0000115 xml:lang="en">a core relation that holds between a whole and its part</obo:IAO_0000115>
        <obo:IAO_0000118 xml:lang="en">has_part</obo:IAO_0000118>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ro.owl"/>
        <rdfs:label xml:lang="en">has_part</rdfs:label>
    </owl:ObjectProperty>
    


    <!-- http://purl.obolibrary.org/obo/RO_0000087 -->

    <owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/RO_0000087">
        <obo:IAO_0000115 xml:lang="en">a relation between an independent continuant (the bearer) and a role, in which the role specifically depends on the bearer for its existence</obo:IAO_0000115>
        <obo:IAO_0000118 xml:lang="en">has_role</obo:IAO_0000118>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ro.owl"/>
        <rdfs:label xml:lang="en">has_role</rdfs:label>
    </owl:ObjectProperty>
    


    <!-- http://purl.obolibrary.org/obo/RO_0001000 -->

    <owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/RO_0001000">
        <obo:IAO_0000115 xml:lang="en">a relation between two distinct material entities, the new entity and the old entity, in which the new entity begins to exist when the old entity ceases to exist, and the new entity inherits the significant portion of the matter of the old entity</obo:IAO_0000115>
        <obo:IAO_0000118 xml:lang="en">derives_from</obo:IAO_0000118>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ro.owl"/>
        <rdfs:label xml:lang="en">derives_from</rdfs:label>
    </owl:ObjectProperty>
    


    <!-- http://purl.obolibrary.org/obo/RO_0002202 -->

    <owl:ObjectProperty rdf:about="http://purl.obolibrary.org/obo/RO_0002202">
        <rdf:type rdf:resource="http://www.w3.org/2002/07/owl#TransitiveProperty"/>
        <obo:IAO_0000115>x develops from y if and only if either (a) x directly develops from y or (b) there exists some z such that x directly develops from z and z develops from y</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ro.owl"/>
        <rdfs:label xml:lang="en">develops_from</rdfs:label>
    </owl:ObjectProperty>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Classes
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://purl.obolibrary.org/obo/IMR_0002095 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IMR_0002095">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/imr.owl"/>
        <rdfs:label>Heavy Chain</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IMR_0002096 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IMR_0002096">
        <obo:IAO_0000115>Higher vertebrates have two types of light chains, kappa and lamda, which seem to be functionally indistinguishable. Either type of light chain may be associated with any of the heavy chains.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/imr.owl"/>
        <rdfs:label>Light Chain</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IMR_0002098 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IMR_0002098">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IMR_0002095"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/imr.owl"/>
        <rdfs:label>alpha heavy chain</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IMR_0002099 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IMR_0002099">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IMR_0002095"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/imr.owl"/>
        <rdfs:label>delta heavy chain</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IMR_0002100 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IMR_0002100">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IMR_0002095"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/imr.owl"/>
        <rdfs:label>epsilon heavy chain</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IMR_0002101 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IMR_0002101">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IMR_0002095"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/imr.owl"/>
        <rdfs:label>gamma heavy chain</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IMR_0002102 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IMR_0002102">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IMR_0002096"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/imr.owl"/>
        <rdfs:label>kappa light chain</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IMR_0002103 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IMR_0002103">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IMR_0002096"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/imr.owl"/>
        <rdfs:label>lambda light chain</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/IMR_0002104 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/IMR_0002104">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/IMR_0002095"/>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/imr.owl"/>
        <rdfs:label>mu heavy chain</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C102566 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C102566">
        <obo:IAO_0000115>An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent&apos;s efficacy in multidrug resistant tumor cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C39284"/>
        <obo:NCIT_NHC0>C102566</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Mirvetuximab Soravtansine</obo:NCIT_P107>
        <obo:NCIT_P108>Mirvetuximab Soravtansine</obo:NCIT_P108>
        <obo:NCIT_P207>C3640818</obo:NCIT_P207>
        <obo:NCIT_P210>1453084-37-1</obo:NCIT_P210>
        <obo:NCIT_P319>98DE7VN88D</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Mirvetuximab Soravtansine</obo:NCIT_P375>
        <obo:NCIT_P399>734941</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>IMGN853</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>M9346A-sulfo-SPDB-DM4</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MIRVETUXIMAB SORAVTANSINE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Mirvetuximab Soravtansine</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Mirvetuximab Soravtansine</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C102783 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C102783">
        <obo:IAO_0000115>An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C18544"/>
        <obo:NCIT_NHC0>C102783</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Sacituzumab Govitecan</obo:NCIT_P107>
        <obo:NCIT_P108>Sacituzumab Govitecan</obo:NCIT_P108>
        <obo:NCIT_P207>C3640943</obo:NCIT_P207>
        <obo:NCIT_P210>1491917-83-9</obo:NCIT_P210>
        <obo:NCIT_P319>M9BYU8XDQ6</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Sacituzumab Govitecan</obo:NCIT_P375>
        <obo:NCIT_P399>736415</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>IMMU-132</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RS7-SN38</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SACITUZUMAB GOVITECAN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Sacituzumab Govitecan</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Sacituzumab Govitecan-hziy</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trodelvy</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>hRS7-SN38 Antibody Drug Conjugate</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Sacituzumab Govitecan</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C103194 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C103194">
        <obo:IAO_0000115>A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C96024"/>
        <obo:NCIT_NHC0>C103194</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Durvalumab</obo:NCIT_P107>
        <obo:NCIT_P108>Durvalumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3641122</obo:NCIT_P207>
        <obo:NCIT_P210>1428935-60-7</obo:NCIT_P210>
        <obo:NCIT_P319>28X28X9OKV</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Durvalumab</obo:NCIT_P375>
        <obo:NCIT_P399>740856</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>DURVALUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Durvalumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Imfinzi</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MEDI-4736</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MEDI4736</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Durvalumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C104012 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C104012">
        <obo:IAO_0000115>A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked to the human IgG1 Fc domain, with red blood cell stimulating activity. Upon subcutaneous administration, luspatercept inhibits several ligands in the transforming growth factor (TGF)-beta superfamily. This prevents activation of a variety of TGF-beta superfamily members involved in late stage erythropoiesis and results in an increased differentiation and proliferation of erythroid progenitors. luspatercept acts at a different, later stage than erythropoietin. This agent ultimately enhances red blood cell production and prevents anemia.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C104012</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Luspatercept</obo:NCIT_P107>
        <obo:NCIT_P108>Luspatercept</obo:NCIT_P108>
        <obo:NCIT_P208>CL438394</obo:NCIT_P208>
        <obo:NCIT_P210>1373715-00-4</obo:NCIT_P210>
        <obo:NCIT_P319>AQK7UBA1LS</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>744051</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>(79-L-aspartic Acid(L&gt;D))Human Activin Receptor Type-2B (ACTR-IIB, EC=2.7.11.30) Precursor-(25-131)-peptide (Extracellular Domain Fragment) Fusion Protein with Triglycyl-human Immunoglobulin Heavy Constant Gamma 1 Fc Fragment-(8-232)-peptide Dimer (114-114&apos;:117-117&apos;)-bisdisulfide</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ACE-536</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LUSPATERCEPT</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Luspatercept</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Luspatercept-aamt</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Reblozyl</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Luspatercept</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C104153 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C104153">
        <obo:IAO_0000115>An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD79B, a component of the B-cell receptor (BCR), plays a key role in B-cell receptor signaling and is expressed on the surface of almost all types of malignant B-cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C97426"/>
        <obo:NCIT_NHC0>C104153</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Polatuzumab Vedotin</obo:NCIT_P107>
        <obo:NCIT_P108>Polatuzumab Vedotin</obo:NCIT_P108>
        <obo:NCIT_P207>C4078806</obo:NCIT_P207>
        <obo:NCIT_P210>1313206-42-6</obo:NCIT_P210>
        <obo:NCIT_P319>KG6VO684Z6</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Polatuzumab Vedotin</obo:NCIT_P375>
        <obo:NCIT_P399>695317</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ADC DCDS4501A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Antibody-Drug Conjugate DCDS4501A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>DCDS4501A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>FCU 2711</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>POLATUZUMAB VEDOTIN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Polatuzumab Vedotin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Polivy</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RG7596</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ro 5541077-000</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>polatuzumab vedotin-piiq</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Polatuzumab Vedotin</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C106250 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C106250">
        <obo:IAO_0000115>A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C96024"/>
        <obo:NCIT_NHC0>C106250</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Atezolizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Atezolizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3827082</obo:NCIT_P207>
        <obo:NCIT_P210>1380723-44-3</obo:NCIT_P210>
        <obo:NCIT_P319>52CMI0WC3Y</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Atezolizumab</obo:NCIT_P375>
        <obo:NCIT_P399>702758</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ATEZOLIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Atezolizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(human CD Antigen cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide with Human Monoclonal MPDL3280A Kappa-chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MPDL 3280A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MPDL 328OA</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MPDL-3280A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MPDL3280A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MPDL328OA</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RG7446</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO5541267</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tecentriq</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Atezolizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C106432 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C106432">
        <obo:IAO_0000115>A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C106432</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Pembrolizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Pembrolizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3658706</obo:NCIT_P207>
        <obo:NCIT_P210>1374853-91-4</obo:NCIT_P210>
        <obo:NCIT_P319>DPT0O3T46P</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P322>PCDC</obo:NCIT_P322>
        <obo:NCIT_P375>Pembrolizumab</obo:NCIT_P375>
        <obo:NCIT_P399>695789</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S&gt;P))gamma 4 Heavy Chain (134-218&apos;)-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226&apos;&apos;:229-229&apos;&apos;)-bisdisulfide</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Keytruda</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Lambrolizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MK-3475</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PEMBROLIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Pembrolizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SCH 900475</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C186327"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C186328"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C186341"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Pembrolizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C111999 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C111999">
        <obo:IAO_0000115>A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T-lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3 is a member of the immunoglobulin superfamily (IgSF) and binds to major histocompatibility complex (MHC) class II. LAG-3 expression on TILs is associated with tumor-mediated immune suppression.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C104623"/>
        <obo:NCIT_NHC0>C111999</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Relatlimab</obo:NCIT_P107>
        <obo:NCIT_P108>Relatlimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL454288</obo:NCIT_P208>
        <obo:NCIT_P210>1673516-98-7</obo:NCIT_P210>
        <obo:NCIT_P319>AF75XOF6W3</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Relatlimab</obo:NCIT_P375>
        <obo:NCIT_P399>754229</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>BMS-986016</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BMS986016</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RELATLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Relatlimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Relatlimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C113164 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C113164">
        <obo:IAO_0000115>An antibody-drug conjugate (ADC) comprised of tisotumab, a monoclonal antibody against human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antiangiogenic, anticoagulant and antineoplastic activities. Upon administration of tisotumab vedotin, the tisotumab moiety binds to cell surface TF and is internalized. Tisotumab binds to factor VIIa (FVIIa), which interferes with the activation of factor X (FX) into FXa. This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. After internalization of the agent, the MMAE moiety is released by proteolytic cleavage. It then binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. TF, a transmembrane protein and initiator of the coagulation cascade, is overexpressed in many tumor cells and tumor-resident endothelial cells. Expression of TF is correlated with metastasis, angiogenesis, tumor cell growth and tumor-associated thrombosis.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17197"/>
        <obo:NCIT_NHC0>C113164</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Tisotumab Vedotin</obo:NCIT_P107>
        <obo:NCIT_P108>Tisotumab Vedotin</obo:NCIT_P108>
        <obo:NCIT_P208>CL455237</obo:NCIT_P208>
        <obo:NCIT_P210>1418731-10-8</obo:NCIT_P210>
        <obo:NCIT_P319>T41737F88A</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Tisotumab Vedotin</obo:NCIT_P375>
        <obo:NCIT_P399>755933</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>HuMax-TF-ADC</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TISOTUMAB VEDOTIN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tisotumab Vedotin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tisotumab Vedotin-tftv</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tivdak</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tisotumab Vedotin</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C114299 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C114299">
        <obo:IAO_0000115>An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), conjugated to mafodotin, an auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration of belantamab mafodotin, the anti-BCMA antibody moiety selectively binds to BCMA on tumor cell surfaces. Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis. In addition, belantamab mafodotin induces antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of cellular proliferation in tumor cells that overexpress BCMA. BCMA, a receptor for a proliferation-inducing ligand and B-cell activating factor, is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. Afucosylation of the antibody moiety increases ADCC.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C97848"/>
        <obo:NCIT_NHC0>C114299</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Belantamab Mafodotin</obo:NCIT_P107>
        <obo:NCIT_P108>Belantamab Mafodotin</obo:NCIT_P108>
        <obo:NCIT_P208>CL471808</obo:NCIT_P208>
        <obo:NCIT_P210>2050232-20-5</obo:NCIT_P210>
        <obo:NCIT_P319>DB1041CXDG</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-BCMA Antibody-drug Conjugate GSK2857916</obo:NCIT_P375>
        <obo:NCIT_P375>Belantamab Mafodotin</obo:NCIT_P375>
        <obo:NCIT_P399>758317</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>BELANTAMAB MAFODOTIN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Belantamab Mafodotin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Belantamab Mafodotin-blmf</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Blenrep</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GSK2857916</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>J6M0-mcMMAF</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Belantamab Mafodotin</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C114500 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C114500">
        <obo:IAO_0000115>An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_NHC0>C114500</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Enfortumab Vedotin</obo:NCIT_P108>
        <obo:NCIT_P208>CL472325</obo:NCIT_P208>
        <obo:NCIT_P210>1346452-25-2</obo:NCIT_P210>
        <obo:NCIT_P319>DLE8519RWM</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E</obo:NCIT_P375>
        <obo:NCIT_P375>Enfortumab Vedotin</obo:NCIT_P375>
        <obo:NCIT_P399>759429</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AGS 22ME</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AGS-22M6E</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ASG-22CE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-Nectin 4 ADC ASG-22CE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ENFORTUMAB VEDOTIN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Enfortumab Vedotin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Enfortumab Vedotin-ejfv</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Padcev</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Enfortumab Vedotin</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C116870 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C116870">
        <obo:IAO_0000115>A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C96024"/>
        <obo:NCIT_NHC0>C116870</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Avelumab</obo:NCIT_P107>
        <obo:NCIT_P108>Avelumab</obo:NCIT_P108>
        <obo:NCIT_P207>C4055417</obo:NCIT_P207>
        <obo:NCIT_P210>1537032-82-8</obo:NCIT_P210>
        <obo:NCIT_P319>KXG2PJ551I</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Avelumab</obo:NCIT_P375>
        <obo:NCIT_P399>745752</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AVELUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Avelumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bavencio</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1, pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MSB-0010718C</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MSB0010718C</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Avelumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C118674 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C118674">
        <obo:IAO_0000115>An antibody-drug conjugate (ADC) composed of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole (seco-DUBA), with potential antineoplastic activity. Upon administration of trastuzumab duocarmazine, the trastuzumab moiety binds to HER2 on the tumor cell surface, which triggers the endocytosis of this agent. The linker is then cleaved inside the tumor cell by proteases at the dipeptide valine-citrulline (vc), and releases the active moiety, duocarmycin. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death. In addition, trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2 is overexpressed by many carcinomas and is associated with a poor prognosis.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17319"/>
        <obo:NCIT_NHC0>C118674</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Trastuzumab Duocarmazine</obo:NCIT_P107>
        <obo:NCIT_P108>Trastuzumab Duocarmazine</obo:NCIT_P108>
        <obo:NCIT_P207>C3896762</obo:NCIT_P207>
        <obo:NCIT_P210>1642152-40-6</obo:NCIT_P210>
        <obo:NCIT_P319>XCR2BZ80N7</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Trastuzumab Duocarmazine</obo:NCIT_P375>
        <obo:NCIT_P399>766012</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ADC SYD985</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Antibody-drug Conjugate SYD985</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SYD985</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TRASTUZUMAB DUOCARMAZINE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab Duocarmazine</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab VC-seco-DUBA</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab-drug Conjugate SYD985</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>vic-Trastuzumab Duocarmazine</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Trastuzumab Duocarmazine</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C119744 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C119744">
        <obo:IAO_0000115>An orally bioavailable recombinant human immunoglobulin G1 monoclonal antibody directed against human fibroblast growth factor 23 (FGF23), that can be used to increase serum phosphate levels. Upon subcutaneous administration, burosumab binds to and inhibits FGF23, thereby interfering with FGF23 signaling. This increases tubular phosphate reabsorption, decreases excretion of phosphate, and increases serum phosphate levels, resulting in enhanced bone mineralization. FGF23, a member of the fibroblast growth factor (FGF) family produced by osteocytes, plays a key role in hypophosphatemic rickets/osteomalacia, such as X-linked hypophosphatemia (XLH) and tumor-induced rickets/osteomalacia. Increased FGF23 levels lead to decreased expression of the sodium-phosphate co-transporters in the proximal tubules, reduced renal phosphate reabsorption, increased excretion by the kidneys, and low serum phosphate concentration.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C104384"/>
        <obo:NCIT_NHC0>C119744</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Burosumab</obo:NCIT_P107>
        <obo:NCIT_P108>Burosumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3896830</obo:NCIT_P207>
        <obo:NCIT_P210>1610833-03-8</obo:NCIT_P210>
        <obo:NCIT_P319>G9WJT6RD29</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Burosumab</obo:NCIT_P375>
        <obo:NCIT_P399>767123</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-FGF23 IgG1 Monoclonal Antibody KRN23</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BUROSUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Burosumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Burosumab-TWZA</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Crysvita</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KRN23</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>UX023</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Burosumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C119952 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C119952">
        <obo:IAO_0000115>A monoclonal antibody against mannan-binding lectin (MBL)-associated serine protease-2 (MASP-2), with potential anti-thrombotic and immunomodulating activities. Upon subcutaneous administration, narsoplimab binds to and inhibits MASP-2. This prevents the activation of MASP-2, the cleavage of certain complement components, and the activation of the complement lectin pathway. This inhibits complement deposition and complement-induced thrombus formation. MASP-2, a pro-inflammatory protein, plays a key role in the activation of the lectin complement pathway, which is a key component in the immune system, and is associated with complement-mediated diseases, such as thrombotic microangiopathies (TMAs), which includes hematopoietic stem cell transplant (HSCT)-related TMA, atypical hemolytic uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP).</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C181978"/>
        <obo:NCIT_NHC0>C119952</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Anti-MASP-2 Monoclonal Antibody OMS721</obo:NCIT_P107>
        <obo:NCIT_P108>Narsoplimab</obo:NCIT_P108>
        <obo:NCIT_P207>C3896796</obo:NCIT_P207>
        <obo:NCIT_P210>2108782-45-0</obo:NCIT_P210>
        <obo:NCIT_P319>FT24ZQQ5RP</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>773678</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-MASP-2 Monoclonal Antibody OMS721</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>NARSOPLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Narsoplimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>OMS721</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>WHO 11174</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Narsoplimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C121540 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C121540">
        <obo:IAO_0000115>A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C121540</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Cemiplimab</obo:NCIT_P107>
        <obo:NCIT_P108>Cemiplimab</obo:NCIT_P108>
        <obo:NCIT_P207>C4053601</obo:NCIT_P207>
        <obo:NCIT_P210>1801342-60-8</obo:NCIT_P210>
        <obo:NCIT_P319>6QVL057INT</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Cemiplimab</obo:NCIT_P375>
        <obo:NCIT_P399>770083</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>CEMIPLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cemiplimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cemiplimab RWLC</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cemiplimab-rwlc</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Disulfide with Human Monoclonal REGN2810 kappa-chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Libtayo</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN2810</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Cemiplimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C121775 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C121775">
        <obo:IAO_0000115>A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C121775</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Tislelizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Tislelizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C4053664</obo:NCIT_P207>
        <obo:NCIT_P210>1858168-59-8</obo:NCIT_P210>
        <obo:NCIT_P319>0KVO411B3N</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Tislelizumab</obo:NCIT_P375>
        <obo:NCIT_P399>770893</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>BGB-A317</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TISLELIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tirelizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tislelizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tislelizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C122680 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C122680">
        <obo:IAO_0000115>A chimeric monoclonal antibody directed against human CD20, with potential antineoplastic activity. Ripertamab binds to the B-cell-specific cell surface antigen CD20, which triggers an immune response against CD20-positive B-cells, leading to apoptosis. CD20, a non-glycosylated cell surface phosphoprotein, is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_NHC0>C122680</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Ripertamab</obo:NCIT_P108>
        <obo:NCIT_P207>C4053591</obo:NCIT_P207>
        <obo:NCIT_P210>2249927-04-4</obo:NCIT_P210>
        <obo:NCIT_P319>URS0374MIV</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-CD20 Monoclonal Antibody SCT400</obo:NCIT_P375>
        <obo:NCIT_P399>772859</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CD20 Monoclonal Antibody SCT400</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RIPERTAMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ripertamab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SCT400</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ripertamab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C123428 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C123428">
        <obo:IAO_0000115>A humanized monoclonal antibody directed against the human tumor-associated antigen GD2, with potential antineoplastic activity. Upon vaccination, naxitamab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumor cells. GD2, a disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas. Compared to the murine monoclonal antibody 3F8 (m3F8), the humanized form does not cause a human anti-mouse antibody (HAMA) response and shows enhanced ADCC activity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1110"/>
        <obo:NCIT_NHC0>C123428</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Naxitamab</obo:NCIT_P107>
        <obo:NCIT_P108>Naxitamab</obo:NCIT_P108>
        <obo:NCIT_P207>C4054758</obo:NCIT_P207>
        <obo:NCIT_P210>1879925-92-4</obo:NCIT_P210>
        <obo:NCIT_P319>9K8GNJ2874</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Naxitamab</obo:NCIT_P375>
        <obo:NCIT_P399>778692</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-Gd2 IGG3 Monoclonal Antibody 3f8 Humanized</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Danyelza</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Hu3F8</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Humanized Anti-GD2 Antibody 3F8</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Humanized Monoclonal Antibody Hu3f8-IGG1</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>NAXITAMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Naxitamab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Naxitamab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C123816 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C123816">
        <obo:IAO_0000115>A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SHR-1210 binds to and blocks the binding of PD-1, expressed on activated T-lymphocytes, B-cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T-lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C123816</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Camrelizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Camrelizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL498210</obo:NCIT_P208>
        <obo:NCIT_P210>1798286-48-2</obo:NCIT_P210>
        <obo:NCIT_P319>73096E137E</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Camrelizumab</obo:NCIT_P375>
        <obo:NCIT_P399>775449</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AiRuiKa (TM)</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CAMRELIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Camrelizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Carrizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HR-301210</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SHR 1210</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SHR-1210</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SHR1210</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Camrelizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C124657 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C124657">
        <obo:IAO_0000115>A longer-acting antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, ravulizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). Compared to other anti-C5 antibodies, ALXN1210 is longer-acting and allows for monthly dosing. C5, a complement pathway protein, is expressed at high levels by the liver.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C21539"/>
        <obo:NCIT_NHC0>C124657</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Ravulizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Ravulizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL502889</obo:NCIT_P208>
        <obo:NCIT_P210>1803171-55-2</obo:NCIT_P210>
        <obo:NCIT_P319>C3VX249T6L</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>776919</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ALXN 1210</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ALXN1210</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RAVULIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ravulizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ravulizumab-cwvz</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ultomiris</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ravulizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C124993 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C124993">
        <obo:IAO_0000115>A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), with potential antineoplastic activity. Upon administration, amivantamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and cMet expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and cMet-mediated signaling pathways. In addition, binding results in receptor degradation, which further inhibits EGFR- and cMet-mediated signaling. JNJ-61186372 also causes antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of tumor cell proliferation. EGFR and cMet, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17068"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C18186"/>
        <obo:NCIT_NHC0>C124993</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Amivantamab</obo:NCIT_P107>
        <obo:NCIT_P108>Amivantamab</obo:NCIT_P108>
        <obo:NCIT_P208>CL503840</obo:NCIT_P208>
        <obo:NCIT_P210>2171511-58-1</obo:NCIT_P210>
        <obo:NCIT_P319>0JSR7Z0NB6</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Amivantamab</obo:NCIT_P375>
        <obo:NCIT_P375>Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372</obo:NCIT_P375>
        <obo:NCIT_P399>777269</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AMIVANTAMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Amivantamab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Amivantamab-vmjw</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CNTO-4424</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>JNJ-611</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>JNJ-61186372</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>JNJ61186372</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rybrevant</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Amivantamab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C125549 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C125549">
        <obo:IAO_0000115>An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody conjugated, via a cleavable linker comprised of valine-alanine and maleimide, to a cytotoxic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the monoclonal antibody portion of loncastuximab tesirine targets the cell surface antigen CD19 on various cancer cells. Upon antibody/antigen binding and internalization, the cytotoxic PBD moiety is released. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on a number of B-cell-derived cancers.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38894"/>
        <obo:NCIT_NHC0>C125549</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Loncastuximab Tesirine</obo:NCIT_P107>
        <obo:NCIT_P108>Loncastuximab Tesirine</obo:NCIT_P108>
        <obo:NCIT_P208>CL504277</obo:NCIT_P208>
        <obo:NCIT_P210>1879918-31-6</obo:NCIT_P210>
        <obo:NCIT_P319>7K5O7P6QIU</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Loncastuximab Tesirine</obo:NCIT_P375>
        <obo:NCIT_P399>778954</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ADC ADCT-402</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ADCT-402</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-CD19 PBD-conjugate ADCT-402</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LONCASTUXIMAB TESIRINE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Loncastuximab Tesirine</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Loncastuximab Tesirine-lpyl</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Zynlonta</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Loncastuximab Tesirine</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C126799 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C126799">
        <obo:IAO_0000115>A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C126799</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Dostarlimab</obo:NCIT_P107>
        <obo:NCIT_P108>Dostarlimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL507894</obo:NCIT_P208>
        <obo:NCIT_P210>2022215-59-2</obo:NCIT_P210>
        <obo:NCIT_P319>P0GVQ9A4S5</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-1 Monoclonal Antibody TSR-042</obo:NCIT_P375>
        <obo:NCIT_P375>Dostarlimab</obo:NCIT_P375>
        <obo:NCIT_P399>780223</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ANB011</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>DOSTARLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Dostarlimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Dostarlimab-gxly</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Jemperli</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TSR 042</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TSR-042</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TSR042</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Dostarlimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C127123 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C127123">
        <obo:IAO_0000115>A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration, emapalumab binds to and neutralizes IFNg. This inhibits IFNg-mediated signaling pathways and suppresses the activation of the immune system. IFNg, a cell-signaling protein, plays a key role in the regulation and activation of the immune system; its upregulation is associated with certain auto-immune and auto-inflammatory diseases in which the immune system is abnormally activated.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C20496"/>
        <obo:NCIT_NHC0>C127123</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Emapalumab</obo:NCIT_P107>
        <obo:NCIT_P108>Emapalumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL507913</obo:NCIT_P208>
        <obo:NCIT_P210>1709815-23-5</obo:NCIT_P210>
        <obo:NCIT_P319>3S252O2Z4X</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Emapalumab</obo:NCIT_P375>
        <obo:NCIT_P399>780986</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-IFN gamma Monoclonal Antibody NI-0501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-IFNg mAb NI-0501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-interferon gamma Monoclonal Antibody NI-0501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>EMAPALUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Emapalumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Gamifant</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>NI-0501</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Emapalumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C128625 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C128625">
        <obo:IAO_0000115>A humanized, bivalent anti-von Willebrand factor (VWF) nanobody, with potential anti-platelet and anti-thrombotic activities. Upon administration, caplacizumab specifically binds, with its two identical monovalent moieties, to the A1 domain of the adhesive glycoprotein VWF, thereby inhibiting and neutralizing VWF activity. This prevents the interaction of ultra-large VWF (ULVWF) with the platelet glycoprotein (GP)Ib-IX-V receptor complex, and prevents ULVWF-mediated platelet adhesion, and aggregation, which reduces thrombus formation. VWF is a glycoprotein and plays a key role in blood coagulation. Increased VWF, which is seen in a number of diseases, is associated with an increased risk in thrombosis; in thrombotic thrombocytopenic purpura (TTP), increased levels of ULVWF and thus increased and abnormal platelet aggregation are seen due to impaired breakdown of ULVWF. The nanobody formulation allows for rapid distribution, onset of action and clearance. The nanobody is based on the smallest functional fragments of the immunoglobulin heavy-chain variable domains that occur naturally in the Camelidae family.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C128625</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Caplacizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Caplacizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3713057</obo:NCIT_P207>
        <obo:NCIT_P210>915810-67-2</obo:NCIT_P210>
        <obo:NCIT_P319>2R27AB6766</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>782660</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ALX 0081</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ALX 0681</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ALX-0081</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ALX-0681</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ALX0081</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ALX0681</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CAPLACIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cablivi</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Caplacizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Caplacizumab-yhdp</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Caplacizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C128646 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C128646">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C128646</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Idarucizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3885063</obo:NCIT_P207>
        <obo:NCIT_P210>1362509-93-0</obo:NCIT_P210>
        <obo:NCIT_P319>97RWB5S1U6</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>IDARUCIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Idarucizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Praxbind</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Idarucizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C128799 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C128799">
        <obo:IAO_0000115>An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to deruxtecan, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA topoisomerase 1 (topoisomerase I; Top1) inhibitor, with antineoplastic activity. Upon administration of trastuzumab deruxtecan, trastuzumab targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, deruxtecan binds to and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication, cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. In addition, trastuzumab deruxtecan induces antibody-dependent cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17319"/>
        <obo:NCIT_NHC0>C128799</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Trastuzumab Deruxtecan</obo:NCIT_P107>
        <obo:NCIT_P108>Trastuzumab Deruxtecan</obo:NCIT_P108>
        <obo:NCIT_P208>CL509598</obo:NCIT_P208>
        <obo:NCIT_P210>1826843-81-5</obo:NCIT_P210>
        <obo:NCIT_P319>5384HK7574</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-HER2 ADC DS-8201a</obo:NCIT_P375>
        <obo:NCIT_P375>Trastuzumab Deruxtecan</obo:NCIT_P375>
        <obo:NCIT_P399>783025</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>DS-8201</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>DS-8201a</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Enhertu</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Fam-trastuzumab Deruxtecan-nxki</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TRASTUZUMAB DERUXTECAN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab Deruxtecan</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>WHO 10516</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Trastuzumab Deruxtecan</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C129691 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C129691">
        <obo:IAO_0000115>A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38896"/>
        <obo:NCIT_NHC0>C129691</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Mosunetuzumab</obo:NCIT_P107>
        <obo:NCIT_P108>Mosunetuzumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL507850</obo:NCIT_P208>
        <obo:NCIT_P210>1905409-39-3</obo:NCIT_P210>
        <obo:NCIT_P319>LDJ89SS0YG</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Mosunetuzumab</obo:NCIT_P375>
        <obo:NCIT_P399>774847</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BTCT 4465A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BTCT-4465A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BTCT4465A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CD20/CD3 BiMAb BTCT4465A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MOSUNETUZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Mosunetuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RG 7828</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RG-7828</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RG7828</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO7030816</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Mosunetuzumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C129714 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C129714">
        <obo:IAO_0000115>An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, envafolimab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C96024"/>
        <obo:NCIT_NHC0>C129714</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Envafolimab</obo:NCIT_P107>
        <obo:NCIT_P108>Envafolimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL512904</obo:NCIT_P208>
        <obo:NCIT_P210>2102192-68-5</obo:NCIT_P210>
        <obo:NCIT_P319>ES1M06M6QH</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Envafolimab</obo:NCIT_P375>
        <obo:NCIT_P399>784496</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-PD-L1 MoAb KN035</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ENVAFOLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Envafolimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KN 035</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KN035</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Envafolimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C131334 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C131334">
        <obo:IAO_0000115>A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily that is expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C131334</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Toripalimab</obo:NCIT_P107>
        <obo:NCIT_P108>Toripalimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL514245</obo:NCIT_P208>
        <obo:NCIT_P210>1924598-82-2</obo:NCIT_P210>
        <obo:NCIT_P319>8JXN261VVA</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Toripalimab</obo:NCIT_P375>
        <obo:NCIT_P399>785704</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-PD-1 Monoclonal Antibody JS001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>JS001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TAB 001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TAB-001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TORIPALIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Toripalimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Toripalimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1321 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1321">
        <obo:IAO_0000115>A murine IgG2a monoclonal antibody with immunosuppressive activity. Muromonab-CD3 binds to and inhibits CD3 on the surface of circulating T-lymphocytes; binding of muromonab-CD3 to CD3-positive T cells results in an early activation of this T cell subset, followed by cytokine release, and subsequently inhibition of T cell functions. This agent may cause the opsonization and elimination of CD3-positive T cells from the circulation by mononuclear phagocytes in the liver and spleen. CD3 is part of the functional T cell receptor (TCR) complex, which is necessary for antigen recognition by T cells, and is required for signal transduction.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C1321</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Muromonab-CD3</obo:NCIT_P107>
        <obo:NCIT_P108>Muromonab-CD3</obo:NCIT_P108>
        <obo:NCIT_P207>C0085379</obo:NCIT_P207>
        <obo:NCIT_P210>140608-64-6</obo:NCIT_P210>
        <obo:NCIT_P319>JGA39ICE2V</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.</obo:NCIT_P325>
        <obo:NCIT_P366>Monoclonal_Antibody_OKT3</obo:NCIT_P366>
        <obo:NCIT_P399>39580</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CD3 Monoclonal Antibody OKT3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MUROMONAB-CD3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MoAb OKT3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody OKT3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Muromonab-CD3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Orthoclone OKT3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>muromonab-CD3 monoclonal antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Muromonab-CD3</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C13242 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C13242">
        <obo:IAO_0000115>The portion of an antibody that is invariant within a class of immunoglobulins. It is comprised of the carboxyl terminal half of both light chains and at least three quarters of each heavy chain starting from the carboxyl terminus and excludes the variable regions of the heavy and light chains.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C13242</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid Sequence</obo:NCIT_P106>
        <obo:NCIT_P108>Immunoglobulin Constant Region</obo:NCIT_P108>
        <obo:NCIT_P207>C0021008</obo:NCIT_P207>
        <obo:NCIT_P366>Immunoglobulin_Constant_Region</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Immunoglobulin Constant Region</oboInOwl:hasExactSynonym>
        <rdfs:label>Immunoglobulin Constant Region</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C13245 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C13245">
        <obo:IAO_0000115>The portion of an antibody molecule that contains the three hypervariable regions in both the heavy and light chains. It is comprised of the amino terminal half of the light chains and at most a third of the heavy chains from the amino termini.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C13245</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P107>Immunoglobulin Variable Region</obo:NCIT_P107>
        <obo:NCIT_P108>Immunoglobulin Variable Region</obo:NCIT_P108>
        <obo:NCIT_P207>C0877857</obo:NCIT_P207>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P366>Immunoglobulin_Variable_Region</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Immunoglobulin Variable Region</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C142799"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C142800"/>
        <rdfs:label>Immunoglobulin Variable Region</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C13246 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C13246">
        <obo:IAO_0000115>Part of an immunoglobulin antibody that binds a specific antigen and consists of both a light chain and part of a heavy chain.  By comparison, natural antibodies consist of two heavy and two light chains.  An FAB (fragment antibody) offers the advantages of smaller size and lower cross-reactivity compared to the complete antibody. (NCI04)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C13246</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P108>Fab Fragment</obo:NCIT_P108>
        <obo:NCIT_P207>C0021031</obo:NCIT_P207>
        <obo:NCIT_P366>Fab_Fragment</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Antigen Binding Fragment</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Fab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Fab Fragment</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin, F(ab) Fragment</oboInOwl:hasExactSynonym>
        <rdfs:label>Fab Fragment</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C13247 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C13247">
        <obo:IAO_0000115>A protein product that results from the digestion of antibodies with papain and is comprised of the second and third constant regions of the antibody heavy chain.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C13247</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P108>Immunoglobulin Fc</obo:NCIT_P108>
        <obo:NCIT_P207>C0021032</obo:NCIT_P207>
        <obo:NCIT_P366>Immunoglobulin_Fc</obo:NCIT_P366>
        <obo:NCIT_P98>Fc is an abbreviation for fragment crystalizable because these protein fragments form crystals easily.</obo:NCIT_P98>
        <oboInOwl:hasExactSynonym>Fc Fragment</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Fragment Crystallizable Region</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin Fc</oboInOwl:hasExactSynonym>
        <rdfs:label>Immunoglobulin Fc</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C132992 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C132992">
        <obo:IAO_0000115>A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C132992</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Sintilimab</obo:NCIT_P107>
        <obo:NCIT_P108>Sintilimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL520576</obo:NCIT_P208>
        <obo:NCIT_P210>2072873-06-2</obo:NCIT_P210>
        <obo:NCIT_P319>8FU7FQ8UPK</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Sintilimab</obo:NCIT_P375>
        <obo:NCIT_P399>787603</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-PD-1 Monoclonal Antibody IBI308</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-PDCD1 Monoclonal Antibody IBI308</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IBI 308</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IBI308</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SINTILIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Sintilimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Sintilimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C13342 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C13342">
        <obo:IAO_0000115>Within the variable domain of an antibody molecule are three regions called hypervariable regions, areas of high sequence diversity.  These regions form the surfaces that are responsible for antigen binding interactions.  Also known as complementarity determining region or hypervariable loop.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C13342</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid Sequence</obo:NCIT_P106>
        <obo:NCIT_P108>Immunoglobulin Hypervariable Region</obo:NCIT_P108>
        <obo:NCIT_P207>C0021024</obo:NCIT_P207>
        <obo:NCIT_P366>Immunoglobulin_Hypervariable_Region</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>CDR</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Complementarity Determining Region</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Complementarity-Determining Region</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Hypervariable Loop</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin Hypervariable Region</oboInOwl:hasExactSynonym>
        <rdfs:label>Immunoglobulin Hypervariable Region</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C13343 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C13343">
        <obo:IAO_0000115>A region of relative flexibility between the variable and constant regions of an antibody molecule.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C13343</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P108>Immunoglobulin Hinge Region</obo:NCIT_P108>
        <obo:NCIT_P207>C0312783</obo:NCIT_P207>
        <obo:NCIT_P366>Immunoglobulin_Hinge_Region</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Immunoglobulin Hinge Region</oboInOwl:hasExactSynonym>
        <rdfs:label>Immunoglobulin Hinge Region</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C133543 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C133543">
        <obo:IAO_0000115>A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG) on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell adhesion molecule (CAM), translocates to the surface of activated endothelial cells and platelets, upon stimulation, where it binds to its ligand and mediates the rolling of platelets and neutrophils on activated endothelial cells. Therefore, blockade of p-selectin may inhibit platelet aggregation, maintain blood flow and minimize sickle cell-related pain crises (SCPC).</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17522"/>
        <obo:NCIT_NHC0>C133543</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Crizanlizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Crizanlizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL519758</obo:NCIT_P208>
        <obo:NCIT_P210>1690318-25-2</obo:NCIT_P210>
        <obo:NCIT_P319>L7451S9126</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>788634</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>CRIZANLIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Crizanlizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SEG101</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SelG1</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Crizanlizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C136823 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C136823">
        <obo:IAO_0000115>A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, teclistamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C97848"/>
        <obo:NCIT_NHC0>C136823</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Teclistamab</obo:NCIT_P107>
        <obo:NCIT_P108>Teclistamab</obo:NCIT_P108>
        <obo:NCIT_P208>CL524654</obo:NCIT_P208>
        <obo:NCIT_P210>2119595-80-9</obo:NCIT_P210>
        <obo:NCIT_P319>54534MX6Z9</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957</obo:NCIT_P375>
        <obo:NCIT_P375>Teclistamab</obo:NCIT_P375>
        <obo:NCIT_P399>789710</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>JNJ 64007957</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>JNJ-64007957</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>JNJ64007957</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TECLISTAMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Teclistamab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Teclistamab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C142168 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C142168">
        <obo:IAO_0000115>A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C142168</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Retifanlimab</obo:NCIT_P107>
        <obo:NCIT_P108>Retifanlimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL540160</obo:NCIT_P208>
        <obo:NCIT_P210>2226345-85-1</obo:NCIT_P210>
        <obo:NCIT_P319>2Y3T5IF01Z</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-1 Monoclonal Antibody MGA012</obo:NCIT_P375>
        <obo:NCIT_P375>Retifanlimab</obo:NCIT_P375>
        <obo:NCIT_P399>791453</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>INCMGA 0012</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>INCMGA-0012</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>INCMGA00012</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>INCMGA0012</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MGA 012</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MGA-012</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MGA012</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RETIFANLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Retifanlimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Retifanlimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1454 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1454">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C1454</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Bispecific Antibody</obo:NCIT_P108>
        <obo:NCIT_P207>C0206492</obo:NCIT_P207>
        <obo:NCIT_P325>A type of antibody that can bind to two different antigens at the same time. Bispecific antibodies are being studied in the imaging and treatment of cancer. They are made in the laboratory.</obo:NCIT_P325>
        <obo:NCIT_P366>Bispecific_Antibody</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Bispecific Antibodies</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bispecific Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>bispecific antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>bsAb</oboInOwl:hasExactSynonym>
        <rdfs:label>Bispecific Antibody</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C146860 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C146860">
        <obo:IAO_0000115>A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C97848"/>
        <obo:NCIT_NHC0>C146860</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Elranatamab</obo:NCIT_P107>
        <obo:NCIT_P108>Elranatamab</obo:NCIT_P108>
        <obo:NCIT_P208>CL544825</obo:NCIT_P208>
        <obo:NCIT_P210>2408850-14-4</obo:NCIT_P210>
        <obo:NCIT_P319>L0HR9A577V</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135</obo:NCIT_P375>
        <obo:NCIT_P399>792267</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BCMA x CD3 Bispecific Antibody PF-06863135</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BCMA-CD3 Bispecific Ab PF-06863135</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ELRANATAMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Elranatamab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PF 06863135</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PF-06863135</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PF06863135</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RN 613</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RN-613</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RN613</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Elranatamab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C148155 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C148155">
        <obo:IAO_0000115>A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, prolgolimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C148155</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Prolgolimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382578</obo:NCIT_P208>
        <obo:NCIT_P210>2093956-19-3</obo:NCIT_P210>
        <obo:NCIT_P319>W05CP6IT8R</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-1 Monoclonal Antibody BCD-100</obo:NCIT_P375>
        <obo:NCIT_P375>Prolgolimab</obo:NCIT_P375>
        <obo:NCIT_P399>792520</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>BCD 100</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BCD-100</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BCD100</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PROLGOLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Prolgolimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Prolgolimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C148159 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C148159">
        <obo:IAO_0000115>An immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PD1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, geptanolimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C148159</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Geptanolimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL550785</obo:NCIT_P208>
        <obo:NCIT_P210>2348469-43-0</obo:NCIT_P210>
        <obo:NCIT_P319>FME52R2SGN</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>792527</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>APL-501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CBT 501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CBT-501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CBT501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GB-226</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GEPTANOLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Genolimzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Geptanolimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Geptanolimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C148486 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C148486">
        <obo:IAO_0000115>A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38896"/>
        <obo:NCIT_NHC0>C148486</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Glofitamab</obo:NCIT_P107>
        <obo:NCIT_P108>Glofitamab</obo:NCIT_P108>
        <obo:NCIT_P208>CL551055</obo:NCIT_P208>
        <obo:NCIT_P210>2229047-91-8</obo:NCIT_P210>
        <obo:NCIT_P319>06P3KLK2J8</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Glofitamab</obo:NCIT_P375>
        <obo:NCIT_P399>792571</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GLOFITAMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Glofitamab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO 7082859</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO7082859</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Glofitamab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C148535 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C148535">
        <obo:IAO_0000115>An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, adebrelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C96024"/>
        <obo:NCIT_NHC0>C148535</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Adebrelimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL551134</obo:NCIT_P208>
        <obo:NCIT_P210>2247114-85-6</obo:NCIT_P210>
        <obo:NCIT_P319>1XBY50W1OX</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-L1 Monoclonal Antibody SHR-1316</obo:NCIT_P375>
        <obo:NCIT_P399>792709</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ADEBRELIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Adebrelimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HTI-1088</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SHR-1316</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Adebrelimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C150390 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C150390">
        <obo:IAO_0000115>An orally available, human, immunoglobulin G1 (IgG1) kappa, monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon administration, guselkumab binds to the p19 subunit of IL-23, thereby blocking the binding of IL-23 to the IL-23 receptor. This inhibits IL-23-mediated signaling and the differentiation of CD4-positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated immune responses and inhibits the production of pro-inflammatory cytokines. This may prevent or reduce symptoms and severity of immune-mediated inflammatory disorders. IL-23 plays a key role in the regulation of inflammation and the immune system, and modulates the release of various pro-inflammatory cytokines and chemokines. It is upregulated in various immune-mediated inflammatory disorders.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C61152"/>
        <obo:NCIT_NHC0>C150390</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Guselkumab</obo:NCIT_P107>
        <obo:NCIT_P108>Guselkumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3852217</obo:NCIT_P207>
        <obo:NCIT_P210>1350289-85-8</obo:NCIT_P210>
        <obo:NCIT_P319>089658A12D</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Guselkumab</obo:NCIT_P375>
        <obo:NCIT_P399>792847</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>CNTO 1959</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GUSELKUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Guselkumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tremfya</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Guselkumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1511 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1511">
        <obo:IAO_0000115>Monoclonal antibodies (MoAb) conjugated with radioisotopes, i.e., I-131, Y-90, T-99, or In-111. Using radioimmunoconjugates in radiotherapy or radioimaging has the advantage of targeting cells carrying specific antigens, thereby limiting toxic effects on normal cells. Tumor eradication can be achieved by either the antibody-mediated immune response or by only the cytotoxic activity of the radiation.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C1511</obo:NCIT_NHC0>
        <obo:NCIT_P106>Chemical Viewed Functionally</obo:NCIT_P106>
        <obo:NCIT_P108>Radioimmunoconjugate</obo:NCIT_P108>
        <obo:NCIT_P207>C0243019</obo:NCIT_P207>
        <obo:NCIT_P366>Radioimmunoconjugate</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Radioimmunoconjugate</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Radiolabeled Antibodies</oboInOwl:hasExactSynonym>
        <rdfs:label>Radioimmunoconjugate</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1512 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1512">
        <obo:IAO_0000115>An agent that consists of an immune substance, such as a monoclonal antibody, antigen or an immunoglobulin, and covalently bound to other molecule(s), usually either a toxin, a radioisotope, or a cytotoxic agent. Immunoconjugates allow for specific delivery of certain substances to specific cells or tissues for diagnostic or therapeutic purposes.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C1512</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Immunoconjugate</obo:NCIT_P108>
        <obo:NCIT_P207>C0243020</obo:NCIT_P207>
        <obo:NCIT_P366>Immunoconjugate</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Icon</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoconjugate</oboInOwl:hasExactSynonym>
        <rdfs:label>Immunoconjugate</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C151947 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C151947">
        <obo:IAO_0000115>An immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cosibelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death protein 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C96024"/>
        <obo:NCIT_NHC0>C151947</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Anti-PD-L1 Monoclonal Antibody TG-1501</obo:NCIT_P107>
        <obo:NCIT_P108>Cosibelimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL937684</obo:NCIT_P208>
        <obo:NCIT_P210>2216751-26-5</obo:NCIT_P210>
        <obo:NCIT_P319>PNW7GBB44P</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-L1 Monoclonal Antibody CK-301</obo:NCIT_P375>
        <obo:NCIT_P375>Anti-PD-L1 Monoclonal Antibody TG-1501</obo:NCIT_P375>
        <obo:NCIT_P375>Cosibelimab</obo:NCIT_P375>
        <obo:NCIT_P399>793157</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-PD-L1 Monoclonal Antibody TG-1501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-PDL1 Monoclonal Antibody TG-1501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CK 301</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CK-301</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>COSIBELIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cosibelimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TG 1501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TG-1501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TG1501</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Cosibelimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C152160 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C152160">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C152160</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Raxibacumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL553492</obo:NCIT_P208>
        <obo:NCIT_P210>565451-13-0</obo:NCIT_P210>
        <obo:NCIT_P319>794PGL549S</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>RAXIBACUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Raxibacumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Raxibacumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C152197 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C152197">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C152197</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Reslizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL553401</obo:NCIT_P208>
        <obo:NCIT_P210>241473-69-8</obo:NCIT_P210>
        <obo:NCIT_P319>35A26E427H</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>RESLIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Reslizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Reslizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C152227 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C152227">
        <obo:IAO_0000115>A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the p19 subunit of human interleukin 23 (IL-23) cytokine, with anti-inflammatory activity. Upon administration, risankizumab targets and binds to the p19 subunit of human IL-23, inhibiting the interaction of IL-23 with the IL-23 receptor complex. This inhibits IL-23/IL-23 receptor-mediated signaling and inhibits the release of pro-inflammatory cytokines and chemokines. IL-23 plays an important role in the development, maintenance and activation of Th17 cells, which produce pro-inflammatory cytokines including IL-17A, IL-17F, and IL-22. It is upregulated in various inflammatory and autoimmune diseases.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C152227</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Risankizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL773300</obo:NCIT_P208>
        <obo:NCIT_P210>1612838-76-2</obo:NCIT_P210>
        <obo:NCIT_P319>90ZX3Q3FR7</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ABBV-066</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BI-655066</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RISANKIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Risankizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Risankizumab-rzaa</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Skyrizi</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Risankizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C152246 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C152246">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C152246</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Romosozumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3661283</obo:NCIT_P207>
        <obo:NCIT_P210>909395-70-6</obo:NCIT_P210>
        <obo:NCIT_P319>3VHF2ZD92J</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ROMOSOZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Romosozumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Romosozumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C152270 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C152270">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C152270</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Rozanolixizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL553602</obo:NCIT_P208>
        <obo:NCIT_P210>1584645-37-3</obo:NCIT_P210>
        <obo:NCIT_P319>P7186074QC</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ROZANOLIXIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rozanolixizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Rozanolixizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C152302 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C152302">
        <obo:IAO_0000115>A recombinant, human immunoglobulin (IgG) monoclonal antibody targeting the interleukin 6 receptor (IL-6R), with potential anti-inflammatory activity. Upon intravenous administration of sarilumab, this agent targets and binds to both soluble IL-6 receptor (sIL-6R) and membrane-bound IL-6 receptor (mIL-6R). This inhibits the binding of the pro-inammatory cytokine IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This may inhibit IL-6/IL-6R-mediated inflammation.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C156002"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38921"/>
        <obo:NCIT_NHC0>C152302</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Sarilumab</obo:NCIT_P107>
        <obo:NCIT_P108>Sarilumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3885145</obo:NCIT_P207>
        <obo:NCIT_P210>1189541-98-7</obo:NCIT_P210>
        <obo:NCIT_P319>NU90V55F8I</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>803539</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-Human Interleukin 6 Receptor alpha) (Human REGN88 Heavy Chain), Disulfide with Human REGN88 Light Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Kevzara</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN88</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SAR153191</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SARILUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Sarilumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Sarilumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C152307 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C152307">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C152307</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Satralizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL553639</obo:NCIT_P208>
        <obo:NCIT_P210>1535963-91-7</obo:NCIT_P210>
        <obo:NCIT_P319>YB18NF020M</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>SATRALIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Satralizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Satralizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C152315 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C152315">
        <obo:IAO_0000115>A recombinant human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin 17A (IL-17A; IL-17), with potential anti-inflammatory activity. Upon subcutaneous administration, secukinumab selectively targets and binds to IL-17A, thereby neutralizing the IL-17A protein. This prevents binding of IL-17A to the IL-17 receptor (IL-17R), and inhibits IL-17A/IL-17R-mediated signaling and inflammation mediated by this pathway. IL-17A is mainly produced by inflammatory T helper 17 cells (Th17), and certain lymphocytes. IL-17A production is upregulated in many immune-mediated inflammatory diseases and plays a key role in the development of inflammation and the immune response.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C152315</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Secukinumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL553647</obo:NCIT_P208>
        <obo:NCIT_P210>1229022-83-6</obo:NCIT_P210>
        <obo:NCIT_P319>DLG4EML025</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>803239</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AIN457</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cosentyx</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SECUKINUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Secukinumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Secukinumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C152582 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C152582">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C152582</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Tezepelumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL553786</obo:NCIT_P208>
        <obo:NCIT_P210>1572943-04-4</obo:NCIT_P210>
        <obo:NCIT_P319>RJ1IW3B4QX</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>TEZEPELUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tezepelumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tezepelumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C152627 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C152627">
        <obo:IAO_0000115>A humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon subcutaneous administration, tildrakizumab targets and binds to the p19 subunit of IL-23, thereby neutralizing IL-23 and preventing the binding of IL-23 to its receptor. This inhibits IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent or reduce symptoms and severity of graft versus host disease (GVHD). IL-23, a pro-inflammatory cytokine that play a key role in the regulation of the immune system, is upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C152627</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Tildrakizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL553831</obo:NCIT_P208>
        <obo:NCIT_P210>1326244-10-3</obo:NCIT_P210>
        <obo:NCIT_P319>DEW6X41BEK</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>799836</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human Interleukin 23) (Human-Mus Musculus Monoclonal Heavy Chain), Disulfide with Human-Mus Musculus Monoclonal Light Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human Interleukin-23); Humanized Mouse Monoclonal Gamma1 Heavy Chain (219-214&apos;)-Disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (225-225&apos;&apos;:228-228&apos;&apos;)-Bisdisulfide</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MK-3222</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TILDRAKIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tildrakizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tildrakizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C152710 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C152710">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C152710</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Tralokinumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3658667</obo:NCIT_P207>
        <obo:NCIT_P210>1044515-88-9</obo:NCIT_P210>
        <obo:NCIT_P319>GK1LYB375A</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>TRALOKINUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tralokinumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tralokinumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C153084 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C153084">
        <obo:IAO_0000115>A human monoclonal antibody directed against Clostridium difficile Toxin B (TcdB), with anti-toxin activity. Upon intravenous infusion, the two Fab regions of bezlotoxumab bind to two distinct epitopes within the N-terminal half of the TcdB combined repetitive oligopeptide (CROP) domain, blocking the carbohydrate binding pockets of the toxin and preventing binding of the toxin to target host cells. TcdB is one of two exotoxins responsible for the symptoms of Clostridium difficile infections.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C153084</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Bezlotoxumab</obo:NCIT_P107>
        <obo:NCIT_P108>Bezlotoxumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL592045</obo:NCIT_P208>
        <obo:NCIT_P210>1246264-45-8</obo:NCIT_P210>
        <obo:NCIT_P319>4H5YMK1H2E</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>793939</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>BEZLOTOXUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bezlotoxumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MK 6072</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MK-6072</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MK6072</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Zinplava</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Bezlotoxumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C153093 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C153093">
        <obo:IAO_0000115>A humanized monoclonal immunoglobulin G4 (IgG4) antibody directed against human compliment factor C1s, with potential immunomodulatory activity. Upon intravenous administration, sutimlimab targets, binds to and blocks the activity of C1s, a portion of the C1 complex, preventing enzymatic action on its substrates, C4 and C2, and inhibiting the formation of C3 convertase. By selectively targeting the classical complement pathway (CP), the function of both the alternative and lectin pathways are preserved. C1s, a serine protease, is responsible for the propagation of the classical complement pathway of the immune system; dysregulation of the classical compliment cascade plays a key role in a variety of complement-mediated disorders.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C153093</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Sutimlimab</obo:NCIT_P107>
        <obo:NCIT_P108>Sutimlimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL554352</obo:NCIT_P208>
        <obo:NCIT_P210>2049079-64-1</obo:NCIT_P210>
        <obo:NCIT_P319>GNWE7KJ995</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>793893</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>BIVV 009</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BIVV-009</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BIVV009</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IPN 009</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IPN-009</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IPN009</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G4, Anti-(Human Complement C1S) (Humanized Mouse Monoclonal TNT009 Gamma4-chain), Disulfide with Humanized Mouse Monoclonal TNT009 Kappa-chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SUTIMLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Sutimlimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TNT009</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>WHO 10757</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Sutimlimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C153379 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C153379">
        <obo:IAO_0000115>A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cadonilimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with cadonilimab may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C153379</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Cadonilimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL554535</obo:NCIT_P208>
        <obo:NCIT_P210>2394841-59-7</obo:NCIT_P210>
        <obo:NCIT_P319>6FYG1DS4NW</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-1/CTLA-4 Bispecific Antibody AK104</obo:NCIT_P375>
        <obo:NCIT_P399>793930</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AK 104</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AK-104</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AK104</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-PD-1 x CTLA-4 Bispecific Antibody AK104</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-PD-1/CTLA-4 Bispecific Antibody AK104</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-PD1/Anti-CTLA4 Bispecific Antibody AK104</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CADONILIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cadonilimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PD-1 x CTLA-4 Dual Checkpoint Inhibitor AK104</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Cadonilimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C154550 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C154550">
        <obo:IAO_0000115>A fully human monoclonal antibody directed against the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sugemalimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells. Anti-PD-L1 monoclonal antibody CS1001 mirrors natural immunoglobulin G4 (IgG4), potentially reducing immunogenicity and other toxicities.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C96024"/>
        <obo:NCIT_NHC0>C154550</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Sugemalimab</obo:NCIT_P107>
        <obo:NCIT_P108>Sugemalimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL555350</obo:NCIT_P208>
        <obo:NCIT_P210>2256084-03-2</obo:NCIT_P210>
        <obo:NCIT_P319>90IQR2I6TR</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-L1 Monoclonal Antibody CS1001</obo:NCIT_P375>
        <obo:NCIT_P375>Sugemalimab</obo:NCIT_P375>
        <obo:NCIT_P399>794350</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-PD-L1 Monoclonal Antibody CS1001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-PD-L1 Monoclonal Antibody WBP 3155</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CS 1001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CS-1001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CS1001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SUGEMALIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Sugemalimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>WBP 315</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>WBP-315</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>WBP315</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Sugemalimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1554 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1554">
        <obo:IAO_0000115>A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body&apos;s immune effector cells, which may exhibit antitumor cytotoxicity. (NCI04)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C20209"/>
        <obo:NCIT_NHC0>C1554</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Edrecolomab</obo:NCIT_P107>
        <obo:NCIT_P108>Edrecolomab</obo:NCIT_P108>
        <obo:NCIT_P207>C0279218</obo:NCIT_P207>
        <obo:NCIT_P210>156586-89-9</obo:NCIT_P210>
        <obo:NCIT_P319>0KYI9U9FSJ</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.</obo:NCIT_P325>
        <obo:NCIT_P366>Edrecolomab</obo:NCIT_P366>
        <obo:NCIT_P375>Edrecolomab</obo:NCIT_P375>
        <obo:NCIT_P399>39352</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>EDRECOLOMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Edrecolomab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G2A (Mouse Monoclonal 17-1A Gamma-Chain Anti-Human Colon Cancer Tumor-Associated Antigen), Disulfide With Mouse Monoclonal 17-1A Light Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MOAB 17-1A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody 17-1A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Panorex</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>edrecolomab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Edrecolomab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C155879 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C155879">
        <obo:IAO_0000115>A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, penpulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C155879</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Penpulimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL562705</obo:NCIT_P208>
        <obo:NCIT_P210>2350298-92-7</obo:NCIT_P210>
        <obo:NCIT_P319>IBS1BZ4E4I</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-1 Monoclonal Antibody AK105</obo:NCIT_P375>
        <obo:NCIT_P399>794779</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AK 105</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AK-105</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AK105</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-PD-1 Monoclonal Antibody AK105</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PENPULIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Penpulimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Penpulimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C156738 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C156738">
        <obo:IAO_0000115>A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, serplulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C156738</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Serplulimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL935905</obo:NCIT_P208>
        <obo:NCIT_P210>2231029-82-4</obo:NCIT_P210>
        <obo:NCIT_P319>S3GQZ2K36V</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-1 Monoclonal Antibody HLX10</obo:NCIT_P375>
        <obo:NCIT_P375>Serplulimab</obo:NCIT_P375>
        <obo:NCIT_P399>795682</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>HLX 10</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HLX-10</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HLX10</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SERPLULIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Serplulimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Serplulimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1569 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1569">
        <obo:IAO_0000115>A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_NHC0>C1569</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Daclizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Daclizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C0663182</obo:NCIT_P207>
        <obo:NCIT_P210>152923-56-3</obo:NCIT_P210>
        <obo:NCIT_P319>CUJ2MVI71Y</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count).</obo:NCIT_P325>
        <obo:NCIT_P366>Daclizumab</obo:NCIT_P366>
        <obo:NCIT_P375>Daclizumab</obo:NCIT_P375>
        <obo:NCIT_P399>42006</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-Tac</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-Tac Humanized Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-Tac Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>DACLIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Dacliximab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Daclizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Humanized Anti-Tac Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody Anti-Tac</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Zenapax</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>daclizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Daclizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1570 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1570">
        <obo:IAO_0000115>A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1110"/>
        <obo:NCIT_NHC0>C1570</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Dinutuximab</obo:NCIT_P107>
        <obo:NCIT_P108>Dinutuximab</obo:NCIT_P108>
        <obo:NCIT_P207>C3871452</obo:NCIT_P207>
        <obo:NCIT_P210>1363687-32-4</obo:NCIT_P210>
        <obo:NCIT_P319>7SQY4ZUD30</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P322>PCDC</obo:NCIT_P322>
        <obo:NCIT_P325>A substance being studied in the treatment of cancer. It binds to a molecule called GD2, which is found in greater than normal amounts on some types of cancer cells. This helps cells of the immune system kill the cancer cells. It is a type of monoclonal antibody.</obo:NCIT_P325>
        <obo:NCIT_P366>Monoclonal_Antibody_Ch14_18</obo:NCIT_P366>
        <obo:NCIT_P375>Dinutuximab</obo:NCIT_P375>
        <obo:NCIT_P399>42042</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Ch 14.18UTC</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ch14.18</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>DINUTUXIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Dinutuximab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MOAB Ch14.18</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Unituxin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>monoclonal antibody Ch14.18</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C179478"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C179531"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Dinutuximab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C157376 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C157376">
        <obo:IAO_0000115>A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. Upon subcutaneous administration, mepolizumab selectively binds to IL-5, preventing it from associating with interleukin-5 receptor subunit alpha (IL5RA) on the surface of eosinophils and their progenitors. IL-5 plays a role in the regulation of eosinophil development from hematopoietic progenitors as well as eosinophil maturation, differentiation, mobilization, activation, and survival. IL-5 also play a role in the pathogenesis of some phenotypes of hypereosinophilic syndrome (HES).</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C26269"/>
        <obo:NCIT_NHC0>C157376</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Mepolizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Mepolizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL936998</obo:NCIT_P208>
        <obo:NCIT_P210>196078-29-2</obo:NCIT_P210>
        <obo:NCIT_P319>90Z2UF0E52</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>796922</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Bosatria</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MEPOLIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Mepolizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Nucala</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SB 240563</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SB-240563</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SB240563</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Mepolizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C159541 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C159541">
        <obo:IAO_0000115>A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of hemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by coagulation factor VIII (FVIII); FVIII is missing in HA patients.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C159541</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Emicizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Emicizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL951379</obo:NCIT_P208>
        <obo:NCIT_P210>1610943-06-0</obo:NCIT_P210>
        <obo:NCIT_P319>7NL2E3F6K3</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ACE910</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>EMICIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Emicizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Emicizumab-kxwh</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Hemlibra</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G4-kappa, Bispecific, Anti-(Homo sapiens F9a (Activated Coagulation Factor F9, Activated Coagulation Factor IX) and Anti-(Homo sapiens F10 (Coagulation Factor 10, Coagulation Factor X)), Humanized Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Emicizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C159549 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C159549">
        <obo:IAO_0000115>A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, zimberelimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C159549</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Zimberelimab</obo:NCIT_P107>
        <obo:NCIT_P108>Zimberelimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL951387</obo:NCIT_P208>
        <obo:NCIT_P210>2259860-24-5</obo:NCIT_P210>
        <obo:NCIT_P319>ZBL7O904IL</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-1 Monoclonal Antibody GLS-010</obo:NCIT_P375>
        <obo:NCIT_P399>797805</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AB 122</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AB-122</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AB122</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-PD-1 Monoclonal Antibody GLS-010</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GLS 010</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GLS-010</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GLS010</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>WBP-3055</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ZIMBERELIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Zimberelimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Zimberelimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C160717 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C160717">
        <obo:IAO_0000115>A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pucotenlimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C160717</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Pucotenlimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL969824</obo:NCIT_P208>
        <obo:NCIT_P210>2403647-03-8</obo:NCIT_P210>
        <obo:NCIT_P319>CGA81G3KR5</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-1 Monoclonal Antibody HX008</obo:NCIT_P375>
        <obo:NCIT_P399>797959</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-PD-1 Monoclonal Antibody HX008</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HX 008</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HX-008</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HX008</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PUCOTENLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Pucotenlimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Pucotenlimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C162455 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C162455">
        <obo:IAO_0000115>A recombinant human monoclonal immunoglobulin G4 (IgG4) antibody directed against the alpha chain of the interleukin-4 receptor (IL-4R alpha) with potential immunomodulatory activities. Upon injection, dupilumab selectively binds to the IL-4R alpha chain. This disrupts IL-4/IL-13 signaling and prevents the activation of downstream pathways that mediate type 2 inflammation and may potentially inhibit tumor cell proliferation, survival, and metastasis. IL-4 and IL-13 receptors are present on the surface of numerous cells involved in the pathophysiology of type-2 helper T-cell (Th2) allergic responses, including B-lymphocytes, eosinophils, dendritic cells (DCs), monocytes, macrophages, basophils, keratinocytes, bronchial epithelial cells, endothelial cells, fibroblasts, and airway smooth muscle cells. Additionally, both IL-4 and IL-13 receptors are overexpressed in a variety of cancers and IL-4 and IL-13 and may serve as biomarkers for cancer aggressiveness. IL-4 and IL-13 are thought to be key regulatory cytokines in the tumor microenvironment (TME) and may play a role in the activation of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) that mediate tumor cell survival.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C26268"/>
        <obo:NCIT_NHC0>C162455</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Dupilumab</obo:NCIT_P107>
        <obo:NCIT_P108>Dupilumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3660996</obo:NCIT_P207>
        <obo:NCIT_P210>1190264-60-8</obo:NCIT_P210>
        <obo:NCIT_P319>420K487FSG</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Dupilumab</obo:NCIT_P375>
        <obo:NCIT_P399>798743</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>DUPILUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Dupilumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Dupixent</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN 668</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN-668</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN668</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SAR 231893</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SAR-231893</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SAR231893</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Dupilumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C162504 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C162504">
        <obo:IAO_0000115>A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, socazolimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C96024"/>
        <obo:NCIT_NHC0>C162504</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P108>Socazolimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL970934</obo:NCIT_P208>
        <obo:NCIT_P210>2305043-30-3</obo:NCIT_P210>
        <obo:NCIT_P319>82P4S8Q3FB</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-L1 Monoclonal Antibody ZKAB001</obo:NCIT_P375>
        <obo:NCIT_P399>798649</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-PD-L1 Monoclonal Antibody ZKAB001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-PDL1 Monoclonal Antibody ZKAB001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SOCAZOLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>STI A1014</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>STI-A1014</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>STIA1014</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Socazolimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ZKAB 001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ZKAB-001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ZKAB001</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Socazolimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C162879 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C162879">
        <obo:IAO_0000115>A recombinant, soluble, vascular endothelial growth factor receptor (VEGFR) protein composed of the second immunoglobulin (Ig) domain of VEGFR-1, the third and fourth Ig domains of VEGFR-2, and the constant region (Fc) of human immunoglobulin G1 (IgG1) with potential anti-angiogenic activities. Upon intravitreal injection, conbercept, functioning as a soluble decoy receptor, binds with high affinity to all VEGF-A isoforms, VEGF-B, as well as placenta growth factor (PlGF)-1 and PlGF-2. This prevents the binding of these growth factors to their endogenous receptors, potentially inhibiting angiogenesis and tumor cell growth.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C105598"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C126117"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C126413"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C20450"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C28666"/>
        <obo:NCIT_NHC0>C162879</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Conbercept</obo:NCIT_P108>
        <obo:NCIT_P208>CL973317</obo:NCIT_P208>
        <obo:NCIT_P210>1227158-72-6</obo:NCIT_P210>
        <obo:NCIT_P319>1P05PW62F3</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Conbercept</obo:NCIT_P375>
        <obo:NCIT_P399>798956</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>CONBERCEPT</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Conbercept</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>FP 3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>FP-3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>FP3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KH 902</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KH 903</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KH-902</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KH-903</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KH902</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KH903</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Conbercept</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C163022 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C163022">
        <obo:IAO_0000115>A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_NHC0>C163022</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Epcoritamab</obo:NCIT_P108>
        <obo:NCIT_P208>CL973375</obo:NCIT_P208>
        <obo:NCIT_P210>2134641-34-0</obo:NCIT_P210>
        <obo:NCIT_P319>D6OMY2L0WA</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-CD3/CD20 Bispecific Antibody GEN3013</obo:NCIT_P375>
        <obo:NCIT_P375>Epcoritamab</obo:NCIT_P375>
        <obo:NCIT_P399>798973</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CD20/CD3 Bispecific Antibody GEN3013</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>DuoBody-CD3xCD20</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>EPCORITAMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Epcoritamab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GEN 3013</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GEN-3013</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GEN3013</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Epcoritamab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C163992 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C163992">
        <obo:IAO_0000115>A humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tagitanlimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C96024"/>
        <obo:NCIT_NHC0>C163992</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Tagitanlimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL977261</obo:NCIT_P208>
        <obo:NCIT_P210>2417649-97-7</obo:NCIT_P210>
        <obo:NCIT_P319>GUY458P83P</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-PD-L1 Monoclonal Antibody A167</obo:NCIT_P375>
        <obo:NCIT_P399>799136</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>A 167</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>A-167</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>A167</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-PD-L1 Monoclonal Antibody A167</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KL A167</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KL-A167</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KLA167</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TAGITANLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tagitanlimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tagitanlimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1647 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1647">
        <obo:IAO_0000115>A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17319"/>
        <obo:NCIT_NHC0>C1647</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Trastuzumab</obo:NCIT_P107>
        <obo:NCIT_P108>Trastuzumab</obo:NCIT_P108>
        <obo:NCIT_P207>C0728747</obo:NCIT_P207>
        <obo:NCIT_P210>180288-69-1</obo:NCIT_P210>
        <obo:NCIT_P319>P188ANX8CK</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. Trastuzumab binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Trastuzumab is a type of monoclonal antibody and a type of HER2 receptor antagonist.</obo:NCIT_P325>
        <obo:NCIT_P366>Trastuzumab</obo:NCIT_P366>
        <obo:NCIT_P375>Trastuzumab</obo:NCIT_P375>
        <obo:NCIT_P399>42265</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ABP 980</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ALT02</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-ERB-2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-HER2/c-erbB2 Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-c-ERB-2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-c-erbB2 Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-erbB-2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-erbB2 Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-p185-HER2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HER2 Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Herceptin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Herceptin Biosimilar PF-05280014</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Herceptin Trastuzumab Biosimilar PF-05280014</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Herzuma</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Kanjinti</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MoAb HER2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody HER2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody c-erb-2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ogivri</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ontruzant</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PF-05280014</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO0452317</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SB3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TRASTUZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab Biosimilar ABP 980</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab Biosimilar ALT02</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab Biosimilar HLX02</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab Biosimilar PF-05280014</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab Biosimilar SB3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab Biosimilar SIBP-01</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab-anns</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab-dkst</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab-dttb</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab-pkrb</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab-qyyp</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trazimera</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>c-erb-2 Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>rhuMAb HER2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>trastuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>trastuzumab biosimilar EG12014</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Trastuzumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C166423 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C166423">
        <obo:IAO_0000115>A human immunoglobulin G4 (IgG4) monoclonal antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, pozelimab targets and binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). C5, a complement pathway protein, is expressed at high levels by the liver.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C166423</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Pozelimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL971674</obo:NCIT_P208>
        <obo:NCIT_P210>2096328-94-6</obo:NCIT_P210>
        <obo:NCIT_P319>0JJ21K6L2I</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>801702</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>POZELIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Pozelimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN 3918</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN-3918</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN3918</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>WHO 10945</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Pozelimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C166444 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C166444">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C166444</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Aducanumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL971693</obo:NCIT_P208>
        <obo:NCIT_P210>1384260-65-4</obo:NCIT_P210>
        <obo:NCIT_P319>105J35OE21</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ADUCANUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Aducanumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Aducanumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C166484 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C166484">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C166484</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Donanemab</obo:NCIT_P108>
        <obo:NCIT_P208>CL971483</obo:NCIT_P208>
        <obo:NCIT_P210>1931944-80-7</obo:NCIT_P210>
        <obo:NCIT_P319>1ADB65P1KK</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>DONANEMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Donanemab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Donanemab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C166498 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C166498">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C166498</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Telitacicept</obo:NCIT_P108>
        <obo:NCIT_P208>CL971497</obo:NCIT_P208>
        <obo:NCIT_P210>2136630-26-5</obo:NCIT_P210>
        <obo:NCIT_P319>1FHM3D7Z49</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>TELITACICEPT</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Telitacicept</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Telitacicept</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C166535 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C166535">
        <obo:IAO_0000115>A fully human immunoglobulin G1 (IgG1) monoclonal antibody against plasma kallikrein that can be used for the treatment of hereditary angioedema (HAE). Upon administration, lanadelumab targets and binds to plasma kallikrein, thereby inhibiting its proteolytic activity. This inhibits the cleavage of high-molecular-weight-kininogen (HMWK) into cleaved HMWK (cHMWK) and bradykinin. This in turn may prevent bradykinin-driven vasodilation, the resulting increase in vascular permeability, and the swelling and pain associated with HAE. This may also prevent or improve pulmonary edema not associated with HAE and improve the associated decrease in blood oxygen levels.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C166535</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Lanadelumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL971536</obo:NCIT_P208>
        <obo:NCIT_P210>1426055-14-2</obo:NCIT_P210>
        <obo:NCIT_P319>2372V1TKXK</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>DX-2930</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LANADELUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Lanadelumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Lanadelumab-flyo</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SHP643</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TAK-743</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Takhzyro</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Lanadelumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C166561 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C166561">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C166561</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Obiltoxaximab</obo:NCIT_P108>
        <obo:NCIT_P207>C4224790</obo:NCIT_P207>
        <obo:NCIT_P210>1351337-07-9</obo:NCIT_P210>
        <obo:NCIT_P319>29Z5DNL48C</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>OBILTOXAXIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Obiltoxaximab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Obiltoxaximab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C166658 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C166658">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C166658</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Anifrolumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL971907</obo:NCIT_P208>
        <obo:NCIT_P210>1326232-46-5</obo:NCIT_P210>
        <obo:NCIT_P319>38RL9AE51Q</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ANIFROLUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anifrolumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Anifrolumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C166816 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C166816">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C166816</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Galcanezumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL971810</obo:NCIT_P208>
        <obo:NCIT_P210>1578199-75-3</obo:NCIT_P210>
        <obo:NCIT_P319>55KHL3P693</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>GALCANEZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Galcanezumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Galcanezumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C166849 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C166849">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C166849</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Spesolimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL971841</obo:NCIT_P208>
        <obo:NCIT_P210>2097104-58-8</obo:NCIT_P210>
        <obo:NCIT_P319>5IB2J79MCX</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>SPESOLIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Spesolimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Spesolimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C166914 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C166914">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C166914</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Concizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL972162</obo:NCIT_P208>
        <obo:NCIT_P210>1312299-39-0</obo:NCIT_P210>
        <obo:NCIT_P319>68603V9EAF</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>CONCIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Concizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Concizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C166971 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C166971">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C166971</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Brodalumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL972217</obo:NCIT_P208>
        <obo:NCIT_P210>1174395-19-7</obo:NCIT_P210>
        <obo:NCIT_P319>6ZA31Y954Z</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>BRODALUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Brodalumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Brodalumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C167039 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C167039">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C167039</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Efmoroctocog Alfa</obo:NCIT_P108>
        <obo:NCIT_P207>C3834055</obo:NCIT_P207>
        <obo:NCIT_P210>1270012-79-7</obo:NCIT_P210>
        <obo:NCIT_P319>7PCM518YLR</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>EFMOROCTOCOG ALFA</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Efmoroctocog Alfa</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Efmoroctocog Alfa</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1681 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1681">
        <obo:IAO_0000115>A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38908"/>
        <obo:NCIT_NHC0>C1681</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Alemtuzumab</obo:NCIT_P107>
        <obo:NCIT_P108>Alemtuzumab</obo:NCIT_P108>
        <obo:NCIT_P207>C0383429</obo:NCIT_P207>
        <obo:NCIT_P210>216503-57-0</obo:NCIT_P210>
        <obo:NCIT_P319>3A189DH42V</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A type of monoclonal antibody used in the treatment of leukemia. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.</obo:NCIT_P325>
        <obo:NCIT_P366>Alemtuzumab</obo:NCIT_P366>
        <obo:NCIT_P375>Alemtuzumab</obo:NCIT_P375>
        <obo:NCIT_P399>37783</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ALEMTUZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Alemtuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-CD52 Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Campath</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Campath-1H</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LDP-03</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Lemtrada</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MabCampath</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody Campath-1H</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>alemtuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Alemtuzumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C169793 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C169793">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C169793</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Atoltivimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382129</obo:NCIT_P208>
        <obo:NCIT_P210>2135632-29-8</obo:NCIT_P210>
        <obo:NCIT_P319>FJZ07Q63VY</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ATOLTIVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Atoltivimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Atoltivimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C169818 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C169818">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C169818</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Brolucizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382174</obo:NCIT_P208>
        <obo:NCIT_P210>1531589-13-5</obo:NCIT_P210>
        <obo:NCIT_P319>XSZ53G39H5</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>BROLUCIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Brolucizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Brolucizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C169867 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C169867">
        <obo:IAO_0000115>A humanized recycling monoclonal antibody directed against the complement pathway protein C5, with potential complement pathway inhibitory and immunomodulating activities. Upon administration, crovalimab targets and binds to a specific C5 epitope, thereby preventing C5 convertase-mediated cleavage of C5, inhibiting the formation of C5a and C5b, and the C5b6 deposition on membranes. This inhibits C5-mediated signal transduction, the formation of the membrane attack complex (MAC) and the activation of the terminal complement pathway. This results in the prevention and/or inhibition of both complement-mediated inflammation and cell destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). C5 plays a key role in the activation of the complement cascade. Crovalimab is engineered with sequential monoclonal antibody recycling technology (SMART).</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C169867</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Crovalimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382222</obo:NCIT_P208>
        <obo:NCIT_P210>1917321-26-6</obo:NCIT_P210>
        <obo:NCIT_P319>H9KH1GP3UU</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>804752</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>CROVALIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Crovalimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO7112689</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SKY59</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Crovalimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C169918 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C169918">
        <obo:IAO_0000115>An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-HER2 ADC RC48, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, the cytotoxic agent induces tumor cell apoptosis, through an as of yet not publicly known mechanism. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_NHC0>C169918</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Disitamab Vedotin</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382403</obo:NCIT_P208>
        <obo:NCIT_P210>2136633-23-1</obo:NCIT_P210>
        <obo:NCIT_P319>RB3U3A1S27</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-HER2 Antibody-drug Conjugate RC48</obo:NCIT_P375>
        <obo:NCIT_P399>784850</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ADC RC48</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-HER2 ADC RC48</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-HER2 Antibody-drug Conjugate RC48</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>DISITAMAB VEDOTIN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Disitamab Vedotin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RC48</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Disitamab Vedotin</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C169958 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C169958">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C169958</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Erenumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382459</obo:NCIT_P208>
        <obo:NCIT_P210>1582205-90-0</obo:NCIT_P210>
        <obo:NCIT_P319>I5I8VB78VT</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ERENUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Erenumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Erenumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C169973 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C169973">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C169973</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Evinacumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382454</obo:NCIT_P208>
        <obo:NCIT_P210>1446419-85-7</obo:NCIT_P210>
        <obo:NCIT_P319>T8B2ORP1DW</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>EVINACUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Evinacumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Evinacumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C170146 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C170146">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C170146</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Maftivimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382376</obo:NCIT_P208>
        <obo:NCIT_P210>2135632-36-7</obo:NCIT_P210>
        <obo:NCIT_P319>KOP95331M4</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>MAFTIVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Maftivimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Maftivimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C170182 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C170182">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C170182</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Mirikizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382675</obo:NCIT_P208>
        <obo:NCIT_P210>1884201-71-1</obo:NCIT_P210>
        <obo:NCIT_P319>Z7HVY03PHP</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>MIRIKIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Mirikizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Mirikizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1702 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1702">
        <obo:IAO_0000115>A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38896"/>
        <obo:NCIT_NHC0>C1702</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Rituximab</obo:NCIT_P107>
        <obo:NCIT_P108>Rituximab</obo:NCIT_P108>
        <obo:NCIT_P207>C0393022</obo:NCIT_P207>
        <obo:NCIT_P210>174722-31-7</obo:NCIT_P210>
        <obo:NCIT_P319>4F4X42SYQ6</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A drug used to treat certain types of B-cell non-Hodgkin lymphoma. It is also used with other drugs to treat chronic lymphocytic leukemia and rheumatoid arthritis. It is being studied in the treatment of other types of cancer and other conditions. Rituximab binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. It is a type of monoclonal antibody.</obo:NCIT_P325>
        <obo:NCIT_P366>Rituximab</obo:NCIT_P366>
        <obo:NCIT_P368>CHEBI:64357</obo:NCIT_P368>
        <obo:NCIT_P375>Rituximab</obo:NCIT_P375>
        <obo:NCIT_P399>42613</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ABP 798</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BI 695500</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>C2B8 Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CT-P10</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Chimeric Anti-CD20 Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IDEC-102</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IDEC-C2B8</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IDEC-C2B8 Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MabThera</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody IDEC-C2B8</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PF-05280586</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RITUXIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RTXM83</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Riabni</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituxan</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab ABBS</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab ARRX</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab Biosimilar ABP 798</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab Biosimilar BI 695500</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab Biosimilar CT-P10</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab Biosimilar GB241</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab Biosimilar IBI301</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab Biosimilar JHL1101</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab Biosimilar PF-05280586</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab Biosimilar RTXM83</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab Biosimilar SAIT101</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab Biosimilar SIBP-02</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab PVVR</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab-arrx</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rituximab-pvvr</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ruxience</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Truxima</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>rituximab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>rituximab biosimilar TQB2303</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>rituximab-abbs</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Rituximab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C170211 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C170211">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C170211</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Nemolizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382688</obo:NCIT_P208>
        <obo:NCIT_P210>1476039-58-3</obo:NCIT_P210>
        <obo:NCIT_P319>GN465U8B72</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>NEMOLIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Nemolizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Nemolizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C170224 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C170224">
        <obo:IAO_0000115>A Fc-engineered recombinant human immunoglobulin (Ig) G1 kappa monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), that can be used for prophylactic and protective purposes in RSV infections. Upon administration, nirsevimab targets and binds to the F1 and F2 subunits of the RSV fusion (F) protein, thereby locking the RSV F protein in the prefusion conformation and blocking viral entry into the host cell. This neutralizes the virus and prevents syncytia formation. This may prevent RSV and RSV-associated lower respiratory tract infection (LRTI) among infants and young children. RSV F protein, a small envelop glycoprotein, is required for cytopathic syncytia formation resulting from cell-to-cell fusion. It is necessary for viral infection and spreading. Nirsevimab has an extended half-life and one administration may therefore provide seasonal protection against RSV.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C170224</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Nirsevimab</obo:NCIT_P107>
        <obo:NCIT_P108>Nirsevimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382696</obo:NCIT_P208>
        <obo:NCIT_P210>1989556-22-0</obo:NCIT_P210>
        <obo:NCIT_P319>VRN8S9CW5V</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>809898</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>MEDI8897</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>NIRSEVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Nirsevimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Nirsevimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C170242 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C170242">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C170242</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Odesivimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382718</obo:NCIT_P208>
        <obo:NCIT_P210>2135632-30-1</obo:NCIT_P210>
        <obo:NCIT_P319>UY9LQ8P6HW</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ODESIVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Odesivimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Odesivimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C170251 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C170251">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C170251</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Omburtamab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382742</obo:NCIT_P208>
        <obo:NCIT_P210>1895083-75-6</obo:NCIT_P210>
        <obo:NCIT_P319>XQL6783S5T</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>8H9</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>OMBURTAMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Omburtamab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Omburtamab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C170281 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C170281">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C170281</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Pabinafusp Alfa</obo:NCIT_P108>
        <obo:NCIT_P208>CL1382521</obo:NCIT_P208>
        <obo:NCIT_P210>2140211-48-7</obo:NCIT_P210>
        <obo:NCIT_P319>TRF8S0U6ON</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>PABINAFUSP ALFA</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Pabinafusp Alfa</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Pabinafusp Alfa</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C171659 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C171659">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C171659</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Eftrenonacog Alfa</obo:NCIT_P108>
        <obo:NCIT_P208>CL1405653</obo:NCIT_P208>
        <obo:NCIT_P210>1270012-74-2</obo:NCIT_P210>
        <obo:NCIT_P319>02E00T2QDE</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>EFTRENONACOG ALFA</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Eftrenonacog Alfa</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Eftrenonacog Alfa</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C171817 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C171817">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C171817</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Efgartigimod Alfa</obo:NCIT_P108>
        <obo:NCIT_P208>CL1405994</obo:NCIT_P208>
        <obo:NCIT_P210>1821402-21-4</obo:NCIT_P210>
        <obo:NCIT_P319>961YV2O515</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>EFGARTIGIMOD ALFA</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Efgartigimod Alfa</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Efgartigimod Alfa</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C171829 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C171829">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C171829</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Bimekizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1406014</obo:NCIT_P208>
        <obo:NCIT_P210>1418205-77-2</obo:NCIT_P210>
        <obo:NCIT_P319>09495UIM6V</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>BIMEKIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bimekizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Bimekizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C171835 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C171835">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C171835</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Eptinezumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1406008</obo:NCIT_P208>
        <obo:NCIT_P210>1644539-04-7</obo:NCIT_P210>
        <obo:NCIT_P319>8202AY8I7H</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>EPTINEZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Eptinezumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Eptinezumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C171839 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C171839">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C171839</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Tafolecimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1406036</obo:NCIT_P208>
        <obo:NCIT_P210>2225109-03-3</obo:NCIT_P210>
        <obo:NCIT_P319>KV2ZKH0NIM</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>TAFOLECIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tafolecimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tafolecimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C171840 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C171840">
        <obo:IAO_0000115>A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T-cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C147936"/>
        <obo:NCIT_NHC0>C171840</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Talquetamab</obo:NCIT_P107>
        <obo:NCIT_P108>Talquetamab</obo:NCIT_P108>
        <obo:NCIT_P208>CL545429</obo:NCIT_P208>
        <obo:NCIT_P210>2226212-40-2</obo:NCIT_P210>
        <obo:NCIT_P319>4W3KFI3TN3</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564</obo:NCIT_P375>
        <obo:NCIT_P399>792477</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GPRC5D x CD3 Bispecific Antibody JNJ-64407564</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GPRC5D x CD3 DuoBody Antibody JNJ-64407564</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GPRC5D/CD3 DuoBody Antibody JNJ-64407564</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Humanized GPRC5D x CD3 DuoBody Antibody JNJ-64407564</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>JNJ 64407564</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>JNJ-64407564</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>JNJ64407564</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TALQUETAMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Talquetamab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Talquetamab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1723 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1723">
        <obo:IAO_0000115>A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17068"/>
        <obo:NCIT_NHC0>C1723</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Cetuximab</obo:NCIT_P107>
        <obo:NCIT_P108>Cetuximab</obo:NCIT_P108>
        <obo:NCIT_P207>C0995188</obo:NCIT_P207>
        <obo:NCIT_P210>205923-56-4</obo:NCIT_P210>
        <obo:NCIT_P319>PQX0D8J21J</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody used to treat certain types of head and neck cancer, and colorectal cancer that has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Erbitux binds to the epidermal growth factor receptor (EGFR), which is found on the surface of some types of cancer cells.</obo:NCIT_P325>
        <obo:NCIT_P366>Cetuximab</obo:NCIT_P366>
        <obo:NCIT_P375>Cetuximab</obo:NCIT_P375>
        <obo:NCIT_P399>42384</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>CETUXIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cetuximab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cetuximab Biosimilar CDP-1</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cetuximab Biosimilar CMAB009</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cetuximab Biosimilar KL 140</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Chimeric Anti-EGFR Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Chimeric MoAb C225</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Chimeric Monoclonal Antibody C225</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Erbitux</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IMC-C225</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>cetuximab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Cetuximab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C172654 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C172654">
        <obo:IAO_0000115>A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (IL-6), with potential immunomodulating and anti-inflammatory activities. Upon administration, olokizumab targets, binds to and blocks the activity of IL-6, which may inhibit the binding of IL-6 to its receptor interleukin-6 receptor (IL-6R). This may inhibit the IL-6/IL-6R-mediated signal transduction pathway and the associated inflammatory response.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C172654</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Olokizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1406734</obo:NCIT_P208>
        <obo:NCIT_P210>1007223-17-7</obo:NCIT_P210>
        <obo:NCIT_P319>PAI71R1D2W</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>CDP 6038</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CDP-6038</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CDP6038</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>OLOKIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Olokizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Olokizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C173804 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C173804">
        <obo:IAO_0000115>An immunoglobulin G1 (IgG1) monoclonal antibody directed against the human interleukin-6 receptor (IL-6R; IL6R; CD126), with potential immunomodulating activity. Upon administration, levilimab targets and binds to the soluble form of IL-6R (sIL-6R; IL-6sR), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C173804</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Levilimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1407730</obo:NCIT_P208>
        <obo:NCIT_P210>2035008-70-7</obo:NCIT_P210>
        <obo:NCIT_P319>P7UV3L2H80</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>BCD 089</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BCD-089</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BCD089</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LEVILIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Levilimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Levilimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C174646 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C174646">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C174646</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Ixekizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1411907</obo:NCIT_P208>
        <obo:NCIT_P210>1143503-69-8</obo:NCIT_P210>
        <obo:NCIT_P319>BTY153760O</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>IXEKIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ixekizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ixekizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C174672 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C174672">
        <obo:IAO_0000115>A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia. Upon administration, evolocumab targets, binds to and inhibits the activity of PCSK9. This prevents binding of PCSK9 to low-density lipoprotein receptor (LDLR) on hepatocytes and prevents its degradation. This increases LDLR on hepatocytes and increases the liver&apos;s ability to remove LDL cholesterol (LDL-C) from the blood, thereby lowering LDL-C levels. PCSK9 binds to LDLR on the surface of hepatocytes to promote LDLR degradation within the liver.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C174672</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Evolocumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1412172</obo:NCIT_P208>
        <obo:NCIT_P210>1256937-27-5</obo:NCIT_P210>
        <obo:NCIT_P319>LKC0U3A8NJ</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>808340</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AMG 145</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AMG-145</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AMG145</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>EVOLOCUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Evolocumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Repatha</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Evolocumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C174842 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C174842">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C174842</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Fremanezumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1412132</obo:NCIT_P208>
        <obo:NCIT_P210>1655501-53-3</obo:NCIT_P210>
        <obo:NCIT_P319>PF8K38CG54</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>FREMANEZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Fremanezumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Fremanezumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C174849 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C174849">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C174849</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Alirocumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1412123</obo:NCIT_P208>
        <obo:NCIT_P210>1245916-14-6</obo:NCIT_P210>
        <obo:NCIT_P319>PP0SHH6V16</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ALIROCUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Alirocumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Alirocumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C174885 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C174885">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C174885</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Faricimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1412159</obo:NCIT_P208>
        <obo:NCIT_P210>1607793-29-2</obo:NCIT_P210>
        <obo:NCIT_P319>QC4F7FKK7I</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>FARICIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Faricimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Faricimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C175105 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C175105">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C175105</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Lecanemab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1412377</obo:NCIT_P208>
        <obo:NCIT_P210>1260393-98-3</obo:NCIT_P210>
        <obo:NCIT_P319>12PYH0FTU9</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>LECANEMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Lecanemab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Lecanemab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C175143 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C175143">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C175143</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Miromavimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1412414</obo:NCIT_P208>
        <obo:NCIT_P210>2247163-73-9</obo:NCIT_P210>
        <obo:NCIT_P319>420IGX81U4</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>MIROMAVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Miromavimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Miromavimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C175159 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C175159">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C175159</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Nebacumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1412398</obo:NCIT_P208>
        <obo:NCIT_P210>138661-01-5</obo:NCIT_P210>
        <obo:NCIT_P319>908FWN27WK</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>NEBACUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Nebacumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Nebacumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C175183 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C175183">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C175183</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Ozoralizumab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1412560</obo:NCIT_P208>
        <obo:NCIT_P210>1167985-17-2</obo:NCIT_P210>
        <obo:NCIT_P319>05ZCK72TXZ</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>OZORALIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ozoralizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ozoralizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C175226 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C175226">
        <obo:IAO_0000115>A neutralizing human monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for passive immunization against COVID-19. Upon administration, romlusevimab specifically targets and binds to a specific epitope on the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C175226</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Romlusevimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1412583</obo:NCIT_P208>
        <obo:NCIT_P210>2509447-08-7</obo:NCIT_P210>
        <obo:NCIT_P319>SM01RRU9KK</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>Anti-SARS-CoV-2 S Protein Monoclonal Antibody BRII-198</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-SARS-CoV-2 Spike Protein Monoclonal Antibody BRII-198</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BRII 198</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BRII-198</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BRII198</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody BRII-198</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ROMLUSEVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Romlusevimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Romlusevimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C175227 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C175227">
        <obo:IAO_0000115>A neutralizing human monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for passive immunization against COVID-19. Upon administration, amubarvimab specifically targets and binds to a highly conserved epitope on the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C175227</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Amubarvimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1412608</obo:NCIT_P208>
        <obo:NCIT_P210>2509447-07-6</obo:NCIT_P210>
        <obo:NCIT_P319>2AD5KH3SE4</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>AMUBARVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Amubarvimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-SARS-CoV-2 S Protein Monoclonal Antibody BRII-196</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-SARS-CoV-2 Spike Protein Monoclonal Antibody BRII-196</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BRII 196</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BRII-196</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BRII196</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody BRII-196</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Amubarvimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C17561 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C17561">
        <obo:IAO_0000115>A protein in which the coding region of two genes have become in-frame and co-continuous.  Fusion proteins can be formed by chromosomal breakage and/or recombination and also can be experimentally created using recombinant DNA techniques.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C17561</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P108>Fusion Protein</obo:NCIT_P108>
        <obo:NCIT_P207>C0162768</obo:NCIT_P207>
        <obo:NCIT_P325>A protein made from a fusion gene, which is created by joining parts of two different genes. Fusion genes may occur naturally in the body by transfer of DNA between chromosomes. For example, the BCR-ABL gene found in some types of leukemia is a fusion gene that makes the BCR-ABL fusion protein. Fusion genes and proteins can also be made in the laboratory by combining genes or parts of genes from the same or different organisms.</obo:NCIT_P325>
        <obo:NCIT_P366>Fusion_Protein</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Chimera Protein</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Chimeric Protein</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Fusion Protein</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>fusion protein</oboInOwl:hasExactSynonym>
        <rdfs:label>Fusion Protein</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C175743 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C175743">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C175743</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Ansuvimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1413212</obo:NCIT_P208>
        <obo:NCIT_P210>2375952-29-5</obo:NCIT_P210>
        <obo:NCIT_P319>TG8IQ19NG2</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ANSUVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ansuvimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ansuvimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C175773 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C175773">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C175773</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Docaravimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1413182</obo:NCIT_P208>
        <obo:NCIT_P210>2247196-23-0</obo:NCIT_P210>
        <obo:NCIT_P319>I0HK032RR6</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>DOCARAVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Docaravimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Docaravimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C175830 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C175830">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C175830</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Netakimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1413254</obo:NCIT_P208>
        <obo:NCIT_P210>1796570-08-5</obo:NCIT_P210>
        <obo:NCIT_P319>D3IAG45DAK</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>NETAKIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Netakimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Netakimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C177058 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C177058">
        <obo:IAO_0000115>A neutralizing human monoclonal antibody isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, cilgavimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C177058</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Cilgavimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1642840</obo:NCIT_P208>
        <obo:NCIT_P210>2420563-99-9</obo:NCIT_P210>
        <obo:NCIT_P319>1KUR4BN70F</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>AZD 1061</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AZD-1061</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AZD1061</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CILGAVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>COV2-2130</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cilgavimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Cilgavimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C177059 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C177059">
        <obo:IAO_0000115>A neutralizing human monoclonal antibody directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, sotrovimab specifically targets and binds to an epitope on the SARS-CoV-2 S protein that is shared with SARS-CoV-1, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C178209"/>
        <obo:NCIT_NHC0>C177059</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Sotrovimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1656267</obo:NCIT_P208>
        <obo:NCIT_P210>2423014-07-5</obo:NCIT_P210>
        <obo:NCIT_P319>1MTK0BPN8V</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>808345</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-SARS-CoV-2 Spike Protein Monoclonal Antibody VIR-7831</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GSK 4182136</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GSK-4182136</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GSK4182136</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SOTROVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Sotrovimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>VIR 7831</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>VIR-7831</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>VIR7831</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Sotrovimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C177063 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C177063">
        <obo:IAO_0000115>A recombinant, human immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, imdevimab specifically targets and binds to the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C177063</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Imdevimab</obo:NCIT_P107>
        <obo:NCIT_P108>Imdevimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1642857</obo:NCIT_P208>
        <obo:NCIT_P210>2415933-40-1</obo:NCIT_P210>
        <obo:NCIT_P319>2Z3DQD2JHM</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>IMDEVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Imdevimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN 10987</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN-10987</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN10987</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Imdevimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C177082 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C177082">
        <obo:IAO_0000115>A neutralizing human monoclonal antibody isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, tixagevimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C177082</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Tixagevimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1642820</obo:NCIT_P208>
        <obo:NCIT_P210>CAS 2420564-02-7</obo:NCIT_P210>
        <obo:NCIT_P319>F0LZ415Z3B</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>AZD 8895</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AZD-8895</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AZD8895</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>COV2-2196</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TIXAGEVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tixagevimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tixagevimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C177084 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C177084">
        <obo:IAO_0000115>A neutralizing, human immunoglobulin G1 (IgG1) monoclonal antibody directed against the spike (S) protein receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against Coronavirus disease 2019 (COVID-19). Upon administration, regdanvimab specifically targets and binds to the RBD of the SARS-CoV-2 S protein. This blocks viral attachment and entry into human host cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may also provide temporary protection against infection with SARS-CoV-2. S-protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C177084</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Regdanvimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1642822</obo:NCIT_P208>
        <obo:NCIT_P210>2444308-95-4</obo:NCIT_P210>
        <obo:NCIT_P319>I0BGE6P6I6</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>CTP 59</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CTP-59</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CTP59</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGDANVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Regdanvimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Regdanvimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C177087 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C177087">
        <obo:IAO_0000115>A recombinant, human immunoglobulin G1 (IgG1) kappa monoclonal antibody directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, casirivimab specifically targets and binds to the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C177087</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Casirivimab</obo:NCIT_P107>
        <obo:NCIT_P108>Casirivimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1642809</obo:NCIT_P208>
        <obo:NCIT_P210>2415933-42-3</obo:NCIT_P210>
        <obo:NCIT_P319>J0FI6WE1QN</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>CASIRIVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Casirivimab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN 10933</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN-10933</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>REGN10933</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Casirivimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1789 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1789">
        <obo:IAO_0000115>A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C20535"/>
        <obo:NCIT_NHC0>C1789</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Infliximab</obo:NCIT_P107>
        <obo:NCIT_P108>Infliximab</obo:NCIT_P108>
        <obo:NCIT_P207>C0666743</obo:NCIT_P207>
        <obo:NCIT_P210>170277-31-3</obo:NCIT_P210>
        <obo:NCIT_P319>B72HH48FLU</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.</obo:NCIT_P325>
        <obo:NCIT_P366>Infliximab</obo:NCIT_P366>
        <obo:NCIT_P375>Infliximab</obo:NCIT_P375>
        <obo:NCIT_P399>38698</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Avakine</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>INFLIXIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Infliximab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Remicade</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Remsima</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>cA2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>infliximab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Infliximab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C179282 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C179282">
        <obo:IAO_0000115>An Fc-engineered monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), with potential immunomodulating and antineoplastic activities. Upon administration, inetetamab targets and specifically binds to HER2 on tumor cells, thereby blocking HER2-mediated signaling. This may inhibit proliferation of HER2-expressing tumor cells. In addition, the Fab region of inetetamab may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C179282</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Inetetamab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1661893</obo:NCIT_P208>
        <obo:NCIT_P399>804693</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Cipterbin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Inetetamab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab Analogue Inetetamab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <rdfs:label>Inetetamab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1806 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1806">
        <obo:IAO_0000115>A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A24 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C274"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C97246"/>
        <obo:NCIT_NHC0>C1806</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Gemtuzumab Ozogamicin</obo:NCIT_P107>
        <obo:NCIT_P108>Gemtuzumab Ozogamicin</obo:NCIT_P108>
        <obo:NCIT_P207>C1533699</obo:NCIT_P207>
        <obo:NCIT_P210>220578-59-6</obo:NCIT_P210>
        <obo:NCIT_P319>8GZG754X6M</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P322>PCDC</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody combined with a toxic substance that is used to treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Mylotarg is a type of antibody-drug conjugate.</obo:NCIT_P325>
        <obo:NCIT_P350>C73H96IN6O25S3</obo:NCIT_P350>
        <obo:NCIT_P366>Gemtuzumab_Ozogamicin</obo:NCIT_P366>
        <obo:NCIT_P375>Gemtuzumab Ozogamicin</obo:NCIT_P375>
        <obo:NCIT_P399>42868</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>CDP-771</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CMA-676</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GEMTUZUMAB OZOGAMICIN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Gemtuzumab Ozogamicin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Mylotarg</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>WAY-CMA-676</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>gemtuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>gemtuzumab ozogamicin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>hP67.6-Calicheamicin</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173234"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C174019"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Gemtuzumab Ozogamicin</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C184868 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C184868">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C184868</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P108>Ormutivimab</obo:NCIT_P108>
        <obo:NCIT_P208>CL1772933</obo:NCIT_P208>
        <obo:NCIT_P210>2449086-91-1</obo:NCIT_P210>
        <obo:NCIT_P319>N7NY3SG25X</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ORMUTIVIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ormutivimab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ormutivimab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C1857 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C1857">
        <obo:IAO_0000115>A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation. (NCI)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17068"/>
        <obo:NCIT_NHC0>C1857</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Panitumumab</obo:NCIT_P107>
        <obo:NCIT_P108>Panitumumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1513448</obo:NCIT_P207>
        <obo:NCIT_P210>339177-26-3</obo:NCIT_P210>
        <obo:NCIT_P319>6A901E312A</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A human monoclonal antibody that is being used to treat colorectal cancer that has spread to other parts of the body. It is used in patients whose disease has not gotten better during or after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. ABX-EGF binds to the epidermal growth factor receptor (EGFR) and may block tumor cell growth.</obo:NCIT_P325>
        <obo:NCIT_P366>Monoclonal_Antibody_ABX-EGF</obo:NCIT_P366>
        <obo:NCIT_P375>Panitumumab</obo:NCIT_P375>
        <obo:NCIT_P399>37857</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ABX-EGF</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ABX-EGF Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ABX-EGF, Clone E7.6.3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>E7.6.3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Human IgG2K Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MoAb ABX-EGF</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MoAb E7.6.3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody ABX-EGF</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody E7.6.3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PANITUMUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Panitumumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Vectibix</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>panitumumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Panitumumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C2039 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C2039">
        <obo:IAO_0000115>A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C20450"/>
        <obo:NCIT_NHC0>C2039</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Bevacizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Bevacizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C0796392</obo:NCIT_P207>
        <obo:NCIT_P210>216974-75-3</obo:NCIT_P210>
        <obo:NCIT_P319>2S9ZZM9Q9V</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A drug used to treat several types of cancer, including certain types of colorectal, lung, breast, and kidney cancers and glioblastoma. It is also being studied in the treatment of other types of cancer. Avastin binds to vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.</obo:NCIT_P325>
        <obo:NCIT_P366>Bevacizumab</obo:NCIT_P366>
        <obo:NCIT_P375>Bevacizumab</obo:NCIT_P375>
        <obo:NCIT_P399>43234</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ABP 215</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-VEGF</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-VEGF Humanized Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-VEGF Monoclonal Antibody SIBP04</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-VEGF rhuMAb</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Avastin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BEVACIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BP102</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BP102 Biosimilar</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar ABP 215</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar BEVZ92</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar BI 695502</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar CBT 124</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar CT-P16</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar FKB238</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar GB-222</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar HD204</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar HLX04</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar IBI305</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar LY01008</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar MIL60</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar MYL-1402O</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar Mvasi</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar QL 1101</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar RPH-001</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar SCT501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab Biosimilar Zirabev</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab awwb</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab-awwb</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Bevacizumab-bvzr</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HD204</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MYL-1402O</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Mvasi</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Recombinant Humanized Anti-VEGF Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SCT501</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SIBP 04</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SIBP-04</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SIBP04</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Zirabev</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>bevacizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>rhuMab-VEGF</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Bevacizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C20401 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C20401">
        <obo:IAO_0000115>An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C20401</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P107>Monoclonal Antibody</obo:NCIT_P107>
        <obo:NCIT_P108>Monoclonal Antibody</obo:NCIT_P108>
        <obo:NCIT_P207>C0003250</obo:NCIT_P207>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P325>A type of protein made in the laboratory that can bind to substances in the body, including tumor cells. There are many kinds of monoclonal antibodies. Each monoclonal antibody is made to find one substance. Monoclonal antibodies are being used to treat some types of cancer and are being studied in the treatment of other types. They can be used alone or to carry drugs, toxins, or radioactive materials directly to a tumor.</obo:NCIT_P325>
        <obo:NCIT_P366>Monoclonal_Antibody</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>MAb</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MoAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibodies</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody Therapy</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>monoclonal antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <rdfs:label>Monoclonal Antibody</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C2381 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C2381">
        <obo:IAO_0000115>A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C20535"/>
        <obo:NCIT_NHC0>C2381</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Etanercept</obo:NCIT_P107>
        <obo:NCIT_P108>Etanercept</obo:NCIT_P108>
        <obo:NCIT_P207>C0717758</obo:NCIT_P207>
        <obo:NCIT_P210>185243-69-0</obo:NCIT_P210>
        <obo:NCIT_P319>OP401G7OJC</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A drug that is commonly used to treat arthritis. It is also being studied in the treatment of cancer, and as a treatment for loss of appetite and weight loss in cancer patients. It belongs to the family of drugs called tumor necrosis factor (TNF) antagonists.</obo:NCIT_P325>
        <obo:NCIT_P366>Etanercept</obo:NCIT_P366>
        <obo:NCIT_P375>Etanercept</obo:NCIT_P375>
        <obo:NCIT_P399>257809</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ETANERCEPT</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Enbrel</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Etanercept</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TNFR:Fc</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tumor Necrosis Factor Receptor IgG Chimera</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>etanercept</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Etanercept</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C2543 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C2543">
        <obo:IAO_0000115>A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells.  Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38896"/>
        <obo:NCIT_NHC0>C2543</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Tositumomab</obo:NCIT_P107>
        <obo:NCIT_P108>Tositumomab</obo:NCIT_P108>
        <obo:NCIT_P207>C0879399</obo:NCIT_P207>
        <obo:NCIT_P210>192391-48-3</obo:NCIT_P210>
        <obo:NCIT_P319>0343IGH41U</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody that is used in the treatment of certain types of non-Hodgkin lymphoma. When tositumomab and iodine I 131 tositumomab (a form of tositumomab that has been chemically changed by adding radioactive iodine) are given together, the combination is called the Bexxar regimen.</obo:NCIT_P325>
        <obo:NCIT_P366>Tositumomab</obo:NCIT_P366>
        <obo:NCIT_P375>Tositumomab</obo:NCIT_P375>
        <obo:NCIT_P399>37818</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CD20 Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MoAb Anti-B1</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody Anti-B1</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TOSITUMOMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tositumomab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>anti-B1</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>tositumomab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tositumomab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C2625 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C2625">
        <obo:IAO_0000115>A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. RSV F protein, a small envelop glycoprotein, is not only required for cytopathic syncytia resulting from cell-to-cell fusion, but is also necessary for viral spreading and evading neutralizing antibody. Palivizumab neutralizes and inhibits fusion activity of RSV, thereby preventing syncytia formation. Administration of this antibody does not interfere with other immunizations.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C2625</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Palivizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C0672596</obo:NCIT_P207>
        <obo:NCIT_P210>188039-54-5</obo:NCIT_P210>
        <obo:NCIT_P319>DQ448MW7KS</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Palivizumab</obo:NCIT_P366>
        <obo:NCIT_P399>38262</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>MEDI 493</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PALIVIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Palivizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Synagis</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Palivizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C2654 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C2654">
        <obo:IAO_0000115>A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17489"/>
        <obo:NCIT_NHC0>C2654</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Ipilimumab</obo:NCIT_P107>
        <obo:NCIT_P108>Ipilimumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1367202</obo:NCIT_P207>
        <obo:NCIT_P210>477202-00-9</obo:NCIT_P210>
        <obo:NCIT_P319>6T8C155666</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody being studied in the treatment of certain types of cancer. Ipilimumab is made in the laboratory and binds to the molecule CTLA-4 on T cells (a type of white blood cell). Ipilimumab may block CTLA-4 and help the immune system kill cancer cells.</obo:NCIT_P325>
        <obo:NCIT_P366>Anti-Cytotoxic_T-Lymphocyte-Associated_Antigen-4_Monoclonal_Antibody</obo:NCIT_P366>
        <obo:NCIT_P375>Ipilimumab</obo:NCIT_P375>
        <obo:NCIT_P399>38447</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BMS-734016</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IPILIMUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ipilimumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ipilimumab Biosimilar CS1002</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MDX-010</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MDX-CTLA4</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Yervoy</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ipilimumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ipilimumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C2682 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C2682">
        <obo:IAO_0000115>A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17293"/>
        <obo:NCIT_NHC0>C2682</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Ziv-Aflibercept</obo:NCIT_P107>
        <obo:NCIT_P108>Ziv-Aflibercept</obo:NCIT_P108>
        <obo:NCIT_P207>C1134659</obo:NCIT_P207>
        <obo:NCIT_P210>862111-32-8</obo:NCIT_P210>
        <obo:NCIT_P319>15C2VL427D</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A substance being studied in the treatment of several types of cancer. Vascular endothelial growth factor trap blocks the action of vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent.</obo:NCIT_P325>
        <obo:NCIT_P366>VEGF_Trap</obo:NCIT_P366>
        <obo:NCIT_P375>Ziv-Aflibercept</obo:NCIT_P375>
        <obo:NCIT_P399>38652</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AFLIBERCEPT</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AVE0005</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Aflibercept</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Eylea</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>VEGF Trap</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>VEGF Trap R1R2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>VEGF-Trap</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Vascular Endothelial Growth Factor Trap</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Zaltrap</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ziv-Aflibercept</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>aflibercept</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>vascular endothelial growth factor trap</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ziv-Aflibercept</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C2733 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C2733">
        <obo:IAO_0000115>A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_NHC0>C2733</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Nimotuzumab</obo:NCIT_P107>
        <obo:NCIT_P108>Nimotuzumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1570482</obo:NCIT_P207>
        <obo:NCIT_P210>828933-51-3</obo:NCIT_P210>
        <obo:NCIT_P319>6NS400BXKH</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Nimotuzumab binds the epidermal growth factor receptor (EGFR) and blocks cancer cells that depend on epidermal growth factor for growth.</obo:NCIT_P325>
        <obo:NCIT_P366>TheraCim_hR3</obo:NCIT_P366>
        <obo:NCIT_P375>Nimotuzumab</obo:NCIT_P375>
        <obo:NCIT_P399>507582</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>H-R3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>NIMOTUZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Nimotuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Thera-CIM-hr3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TheraCim hR3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Theraloc</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>hR3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>nimotuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Nimotuzumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C28161 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C28161">
        <obo:IAO_0000115>Intramuscular injection is a route of drug administration via injection into muscle tissue. Aqueous or oleaginous solutions and emulsions or suspensions may be administered. Absorption rates, delay in availability of the drug to the systemic circulation, and duration of effect are perfusion-limited, depend on molecular size of the agent, volume, and osmolarity of the drug solution, fat content of the injection site, and patient physical activity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C28161</obo:NCIT_NHC0>
        <obo:NCIT_P106>Therapeutic or Preventive Procedure</obo:NCIT_P106>
        <obo:NCIT_P108>Intramuscular Route of Administration</obo:NCIT_P108>
        <obo:NCIT_P207>C1556154</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P322>EDQM-HC</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P322>NICHD</obo:NCIT_P322>
        <obo:NCIT_P325>Administration within a muscle. (FDA)</obo:NCIT_P325>
        <obo:NCIT_P325>Injection of a medicinal product into muscular tissue.</obo:NCIT_P325>
        <obo:NCIT_P366>Intramuscular_Injection</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>IM</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>INTRAMUSCULAR</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Intramuscular</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Intramuscular Injection</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Intramuscular Route of Administration</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Intramuscular use</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>intramuscular injection</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C148636"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C150107"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C54452"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C54455"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66729"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77526"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77527"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C78420"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C78425"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90259"/>
        <rdfs:label>Intramuscular Route of Administration</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C28898 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C28898">
        <obo:IAO_0000115>A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17489"/>
        <obo:NCIT_NHC0>C28898</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Abatacept</obo:NCIT_P107>
        <obo:NCIT_P108>Abatacept</obo:NCIT_P108>
        <obo:NCIT_P207>C1619966</obo:NCIT_P207>
        <obo:NCIT_P210>332348-12-6</obo:NCIT_P210>
        <obo:NCIT_P319>7D0YB67S97</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>CTLA4-Ig</obo:NCIT_P366>
        <obo:NCIT_P399>660119</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ABATACEPT</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Abatacept</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BMS-188667</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CTL A4-Ig B7 Inhibitor</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CTLA4-Ig</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Orencia</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RG2077</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>cytotoxic T lymphocyte-associated antigen-4</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Abatacept</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C29299 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C29299">
        <obo:IAO_0000115>A humanized monoclonal antibody directed against the C-epsilon 3 domain of immunoglobulin E.  Olizumab binds to this IgE domain, thereby preventing IgE from binding to its high-affinity mast-cell receptor. (NCI04)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C29299</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Omalizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C0966225</obo:NCIT_P207>
        <obo:NCIT_P210>242138-07-4</obo:NCIT_P210>
        <obo:NCIT_P319>2P471X1Z11</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Olizumab</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Anti-IgE Monoclonal Antibody E25</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IGE 025</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>OMALIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Olizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Omalizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Xolair</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>rhuMAb-E25</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Omalizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C29981 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C29981">
        <obo:IAO_0000115>An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38896"/>
        <obo:NCIT_NHC0>C29981</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Ibritumomab Tiuxetan</obo:NCIT_P107>
        <obo:NCIT_P108>Ibritumomab Tiuxetan</obo:NCIT_P108>
        <obo:NCIT_P207>C0877880</obo:NCIT_P207>
        <obo:NCIT_P210>206181-63-7</obo:NCIT_P210>
        <obo:NCIT_P319>4Q52C550XK</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment and detection of other types of B-cell tumors. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Ibritumomab binds to the protein called CD20, which is found on B cells. It is linked to the compound tiuxetan. This allows certain radioisotopes to be attached before it is given to a patient. It is a type of monoclonal antibody-chelator conjugate.</obo:NCIT_P325>
        <obo:NCIT_P350>C23H32N5O10S</obo:NCIT_P350>
        <obo:NCIT_P366>Ibritumomab_Tiuxetan</obo:NCIT_P366>
        <obo:NCIT_P375>Ibritumomab Tiuxetan</obo:NCIT_P375>
        <obo:NCIT_P399>43080</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>IBRITUMOMAB TIUXETAN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IDEC-129</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IDEC-2B8</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ibritumomab Tiuxetan</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Zevalin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ibritumomab tiuxetan</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ibritumomab Tiuxetan</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C38274 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C38274">
        <obo:IAO_0000115>A volume of drug intended to be administered into a vein at a relatively fast rate. The volume of drug and the rate of administration are specified.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C38274</obo:NCIT_NHC0>
        <obo:NCIT_P106>Functional Concept</obo:NCIT_P106>
        <obo:NCIT_P108>Intravenous Bolus</obo:NCIT_P108>
        <obo:NCIT_P207>C1522229</obo:NCIT_P207>
        <obo:NCIT_P322>CDISC</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>Administration within or into a vein or veins all at once. (FDA)</obo:NCIT_P325>
        <obo:NCIT_P366>Intravenous_Bolus</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>INTRAVENOUS BOLUS</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IV BOLUS</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IV Bolus</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Intravenous Bolus</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Intravenous Bolus Route of Administration</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C54452"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C54455"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66729"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77526"/>
        <rdfs:label>Intravenous Bolus</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C38275 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C38275">
        <obo:IAO_0000115>Introduction of a drug directly into venous circulation over the time duration of more than 30 minutes but less than 24 hours. Method results in 100% bioavailability of the agent due to an absence of the absorption phase and provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index. To achieve the steady state quickly, the loading dose is used. Intravenously administered drug is diluted in the pooled venous blood and pumped through lungs before entering systematic circulation (lung first-pass effect). The target organ receives only the fraction of drug corresponding to the fraction of received arterial blood.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C38275</obo:NCIT_NHC0>
        <obo:NCIT_P106>Functional Concept</obo:NCIT_P106>
        <obo:NCIT_P107>Intravenous Infusion</obo:NCIT_P107>
        <obo:NCIT_P108>Intravenous Infusion</obo:NCIT_P108>
        <obo:NCIT_P207>C0021440</obo:NCIT_P207>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P325>A method of putting fluids, including drugs, into the bloodstream.</obo:NCIT_P325>
        <obo:NCIT_P366>Intravenous_Infusion</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>IVI</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Intravenous Infusion</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>intravenous infusion</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C118169"/>
        <rdfs:label>Intravenous Infusion</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C38692 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C38692">
        <obo:IAO_0000115>A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17319"/>
        <obo:NCIT_NHC0>C38692</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Pertuzumab</obo:NCIT_P107>
        <obo:NCIT_P108>Pertuzumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1328025</obo:NCIT_P207>
        <obo:NCIT_P210>380610-27-5</obo:NCIT_P210>
        <obo:NCIT_P319>K16AIQ8CTM</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody that is being studied in the treatment of cancer. Monoclonal antibodies are produced in the laboratory and can locate and bind to cancer cells.</obo:NCIT_P325>
        <obo:NCIT_P366>Pertuzumab</obo:NCIT_P366>
        <obo:NCIT_P375>Pertuzumab</obo:NCIT_P375>
        <obo:NCIT_P399>322808</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>2C4</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>2C4 Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HLX11</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HS627</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide with Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MoAb 2C4</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody 2C4</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Omnitarg</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PERTUZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Perjeta</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Pertuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Pertuzumab Biosimilar HLX11</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Pertuzumab Biosimilar HS627</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO4368451</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>pertuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>rhuMAb2C4</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Pertuzumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C48386 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C48386">
        <obo:IAO_0000115>A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C48386</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Eculizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1541483</obo:NCIT_P207>
        <obo:NCIT_P210>219685-50-4</obo:NCIT_P210>
        <obo:NCIT_P319>A3ULP0F556</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody used to prevent red blood cells from being destroyed in patients with paroxysmal nocturnal hemoglobinuria (PNH), a red blood cell disorder. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body. Eculizumab blocks a protein in the blood that causes the breakdown of red blood cells.</obo:NCIT_P325>
        <obo:NCIT_P366>Eculizumab</obo:NCIT_P366>
        <obo:NCIT_P399>415541</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ABP 959</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ABP-959</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ABP959</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Alexion</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BCD 148</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BCD-148</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BCD148</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ECULIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Eculizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Eculizumab Biosimilar ABP 959</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Eculizumab Biosimilar BCD-148</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Eculizumab Biosimilar SB12</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Elizaria</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin, Anti-(Human Complement C5 Alpha-Chain) (Human-Mouse Monoclonal 5G1.1 Heavy Chain), Disulfide with Human-Mouse Monoclonal 5G.1.1 Light Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal antibody 5G1.1</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SB 12</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SB-12</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SB12</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Soliris</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>eculizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>h5G1.1</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Eculizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C49085 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C49085">
        <obo:IAO_0000115>A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17489"/>
        <obo:NCIT_NHC0>C49085</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Tremelimumab</obo:NCIT_P107>
        <obo:NCIT_P108>Tremelimumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2351038</obo:NCIT_P207>
        <obo:NCIT_P210>745013-59-6</obo:NCIT_P210>
        <obo:NCIT_P319>QEN1X95CIX</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody being studied in the treatment of melanoma and some other types of cancer. Ticilimumab is made in the laboratory and binds to a protein called CTLA-4 on T cells (a type of white blood cell). CTLA-4 is involved in preventing the activation of T-cells. Ticilimumab may block CTLA-4 and help the immune system kill cancer cells. It is a type of immunomodulatory agent.</obo:NCIT_P325>
        <obo:NCIT_P366>Anti-CTLA4_Human_Monoclonal_Antibody_CP-675_206</obo:NCIT_P366>
        <obo:NCIT_P375>Tremelimumab</obo:NCIT_P375>
        <obo:NCIT_P399>448620</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CTLA4 Human Monoclonal Antibody CP-675,206</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CP-675</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CP-675,206</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CP-675206</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G2, Anti-(Human CTLA-4 (Antigen)) (Human Monoclonal CP-675206 Clone 11.2.1 Heavy Chain) Disulfide with Human Monoclonal CP-675206 Clone 11.2.1 Light Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TREMELIMUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ticilimumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tremelimumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ticilimumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tremelimumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C52183 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C52183">
        <obo:IAO_0000115>A recombinant protein with megakaryopoiesis stimulating activity. Romiplostim mimics endogenous thrombopoietin (TPO), directly binding to and activating the platelet thrombopoietin receptor (TpoR, Mpl, or CD110 antigen), a cytokine receptor belonging to the hematopoietin receptor superfamily. Activation of TpoR stimulates the proliferation and differentiation of megakaryocytes, resulting in an increase in the production of blood platelets.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17695"/>
        <obo:NCIT_NHC0>C52183</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Romiplostim</obo:NCIT_P107>
        <obo:NCIT_P108>Romiplostim</obo:NCIT_P108>
        <obo:NCIT_P207>C2364481</obo:NCIT_P207>
        <obo:NCIT_P210>267639-76-9</obo:NCIT_P210>
        <obo:NCIT_P319>GN5XU2DXKV</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A drug used to treat patients with immune thrombocytopenic purpura (ITP) who do not get better with other forms of treatment. In ITP, platelets (cells that cause blood clots to form) are destroyed by the immune system. Romiplostim is being studied as a way to treat low platelet counts caused by chemotherapy. It binds to the thrombopoietin receptor and causes the bone marrow to make more platelets. Romiplostim is also being studied in the treatment of myelodysplastic syndromes (a group of diseases in which the bone marrow does not make enough healthy blood cells). It is a type of thrombopoietin agonist.</obo:NCIT_P325>
        <obo:NCIT_P366>AMG531</obo:NCIT_P366>
        <obo:NCIT_P399>459753</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AMG 531</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Amgen Megakaryopoiesis Protein 2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Nplate</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ROMIPLOSTIM</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Romiplostim</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>romiplostim</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Romiplostim</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C52186 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C52186">
        <obo:IAO_0000115>A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17073"/>
        <obo:NCIT_NHC0>C52186</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Basiliximab</obo:NCIT_P107>
        <obo:NCIT_P108>Basiliximab</obo:NCIT_P108>
        <obo:NCIT_P207>C0676831</obo:NCIT_P207>
        <obo:NCIT_P210>179045-86-4</obo:NCIT_P210>
        <obo:NCIT_P319>9927MT646M</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Basiliximab</obo:NCIT_P366>
        <obo:NCIT_P399>459956</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>BASILIXIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Basiliximab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SDZ-CHI-621</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Simulect</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Basiliximab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C565 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C565">
        <obo:IAO_0000115>IgA is the immunoglobulin subclass that is associated with antibody-mediated mucosal immunity.  It is secreted as dimers into the mucosa and is the most effective isotype at fixing complement by the alternative pathway, even though it lacks the ability to fix complement by the classical pathway. There are two subtypes in the human - IgA1 and IgA2.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C565</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P108>IgA</obo:NCIT_P108>
        <obo:NCIT_P207>C0020835</obo:NCIT_P207>
        <obo:NCIT_P366>IgA</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>IgA</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin A</oboInOwl:hasExactSynonym>
        <rdfs:label>IgA</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C566 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C566">
        <obo:IAO_0000115>An immunoglobulin isotype (subclass).  This isotype is expressed on naive B cells along with IgM.  Little is known about its physiologic role.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C566</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P108>IgD</obo:NCIT_P108>
        <obo:NCIT_P207>C0020843</obo:NCIT_P207>
        <obo:NCIT_P366>IgD</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>IgD</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin D</oboInOwl:hasExactSynonym>
        <rdfs:label>IgD</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C567 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C567">
        <obo:IAO_0000115>An immunoglobulin isotype (subclass).  This isotype has the unique ability to bind with high affinity to IgE receptors (FceRI) on mast cells and basophils and induce degranulation and cytokine production by these cells when they are crosslinked by antigen.  In addition to a central role in atopy and allergic responses, it has been speculated that IgE-mediated mast cell degranulation, by its release of mediators that increase vascular permeability, has an important role in the initiation of immune response in general.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C567</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P107>IgE</obo:NCIT_P107>
        <obo:NCIT_P108>IgE</obo:NCIT_P108>
        <obo:NCIT_P207>C0020846</obo:NCIT_P207>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P366>IgE</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>IgE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin E</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C142799"/>
        <rdfs:label>IgE</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C568 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C568">
        <obo:IAO_0000115>An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C568</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P108>IgG</obo:NCIT_P108>
        <obo:NCIT_P207>C0020852</obo:NCIT_P207>
        <obo:NCIT_P366>IgG</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>IgG</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G</oboInOwl:hasExactSynonym>
        <rdfs:label>IgG</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C569 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C569">
        <obo:IAO_0000115>The major immunoglobulin secreted during a primary immune response.  IgM binds with low affinity but high avidity (multiple binding sites) because it not only occurs as monomers but also as pentamers and hexamers.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C569</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P108>IgM</obo:NCIT_P108>
        <obo:NCIT_P207>C0020861</obo:NCIT_P207>
        <obo:NCIT_P366>IgM</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>IgM</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin M</oboInOwl:hasExactSynonym>
        <rdfs:label>IgM</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C575 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C575">
        <obo:IAO_0000115>Agents comprised of various toxic molecules (Radioactive Isotopes and Bacterial or Plant Toxins) conjugated with specific immune substances (Immunoglobulins, Monoclonal Antibodies, and Antigens) that targets affected cells allowing incorporation of the toxin into the cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C575</obo:NCIT_NHC0>
        <obo:NCIT_P106>Chemical Viewed Functionally</obo:NCIT_P106>
        <obo:NCIT_P108>Immunotoxin</obo:NCIT_P108>
        <obo:NCIT_P207>C0021084</obo:NCIT_P207>
        <obo:NCIT_P325>An antibody linked to a toxic substance.  Some immunotoxins can bind to cancer cells and kill them.</obo:NCIT_P325>
        <obo:NCIT_P366>Immunotoxin</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Immunotoxin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>immunotoxin</oboInOwl:hasExactSynonym>
        <rdfs:label>Immunotoxin</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C61084 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C61084">
        <obo:IAO_0000115>A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C20451"/>
        <obo:NCIT_NHC0>C61084</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Siltuximab</obo:NCIT_P107>
        <obo:NCIT_P108>Siltuximab</obo:NCIT_P108>
        <obo:NCIT_P208>CL776663</obo:NCIT_P208>
        <obo:NCIT_P210>541502-14-1</obo:NCIT_P210>
        <obo:NCIT_P319>T4H8FMA7IM</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A chimeric (made from human and mouse proteins) monoclonal antibody being studied in the treatment of advanced kidney cancer and other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Anti-IL-6 chimeric monoclonal antibody works by blocking inflammation and tumor growth.</obo:NCIT_P325>
        <obo:NCIT_P366>Anti-IL-6_Chimeric_Monoclonal_Antibody</obo:NCIT_P366>
        <obo:NCIT_P375>Siltuximab</obo:NCIT_P375>
        <obo:NCIT_P399>475765</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-IL-6 Chimeric Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CNTO 328</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CNTO-328</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SILTUXIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Siltuximab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Sylvant</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>anti-IL-6 chimeric monoclonal antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>cCLB8</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Siltuximab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C61313 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C61313">
        <obo:IAO_0000115>A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C30113"/>
        <obo:NCIT_NHC0>C61313</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Denosumab</obo:NCIT_P107>
        <obo:NCIT_P108>Denosumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1690432</obo:NCIT_P207>
        <obo:NCIT_P210>615258-40-7</obo:NCIT_P210>
        <obo:NCIT_P319>4EQZ6YO2HI</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P322>PCDC</obo:NCIT_P322>
        <obo:NCIT_P325>A type of monoclonal antibody being studied in the treatment of multiple myeloma (a cancer that forms in bones) and in the prevention and treatment of bone metastases (cancer that has spread to bone from another organ). Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. AMG 162 binds to the protein RANKL and helps keep bone from breaking down.</obo:NCIT_P325>
        <obo:NCIT_P366>Densosumab</obo:NCIT_P366>
        <obo:NCIT_P375>Denosumab</obo:NCIT_P375>
        <obo:NCIT_P399>481348</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AMG 162</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>AMG-162</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>DENOSUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Denosumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Denosumab Biosimilar MW032</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Denosumab Biosimilar QL1206</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Denosumab Biosimilar TK-006</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Prolia</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TK-006</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Xgeva</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>denosumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C179478"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C179531"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Denosumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C62445 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C62445">
        <obo:IAO_0000115>A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface antigen expressed by a variety of epithelial tumor cells. In addition, the modified Fc portion of this antibody binds Fc receptors on antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). Catumaxomab brings T cells, EpCAM-expressing epithelial tumor cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against EpCAM-expressing epithelial tumor cells. Fc-mediated binding of APCs in the tricellular complex potentiates EpCAM antigen presentation to T cells and the activation of anti-tumor cytotoxic T cell functions.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C20209"/>
        <obo:NCIT_NHC0>C62445</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Catumaxomab</obo:NCIT_P107>
        <obo:NCIT_P108>Catumaxomab</obo:NCIT_P108>
        <obo:NCIT_P171>17622246</obo:NCIT_P171>
        <obo:NCIT_P207>C1831854</obo:NCIT_P207>
        <obo:NCIT_P210>509077-98-9</obo:NCIT_P210>
        <obo:NCIT_P319>M2HPV837HO</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Catumaxomab</obo:NCIT_P366>
        <obo:NCIT_P375>Catumaxomab</obo:NCIT_P375>
        <obo:NCIT_P399>487002</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>CATUMAXOMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Catumaxomab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Removab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Catumaxomab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C62510 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C62510">
        <obo:IAO_0000115>A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C129067"/>
        <obo:NCIT_NHC0>C62510</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Mogamulizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Mogamulizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2987603</obo:NCIT_P207>
        <obo:NCIT_P210>1159266-37-1</obo:NCIT_P210>
        <obo:NCIT_P319>YI437801BE</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>KW-0761</obo:NCIT_P366>
        <obo:NCIT_P375>Mogamulizumab</obo:NCIT_P375>
        <obo:NCIT_P399>500479</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KM8761</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KW-0761</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MOGAMULIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Mogamulizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Mogamulizumab-kpkc</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Poteligeo</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Mogamulizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C62528 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C62528">
        <obo:IAO_0000115>A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38894"/>
        <obo:NCIT_NHC0>C62528</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Blinatumomab</obo:NCIT_P107>
        <obo:NCIT_P108>Blinatumomab</obo:NCIT_P108>
        <obo:NCIT_P207>C3853839</obo:NCIT_P207>
        <obo:NCIT_P210>853426-35-4</obo:NCIT_P210>
        <obo:NCIT_P319>4FR53SIF3A</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Anti-CD19_Anti-CD3_Bispecific_Monoclonal_Antibody</obo:NCIT_P366>
        <obo:NCIT_P375>Blinatumomab</obo:NCIT_P375>
        <obo:NCIT_P399>487684</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BLINATUMOMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Blinatumomab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Blincyto</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MEDI-538</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MT-103</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Blinatumomab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C63927 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C63927">
        <obo:IAO_0000115>A genetically engineered antibody consisting of both the variable heavy chain (VH) and the light chain (VL) of an immunoglobulin. These entities are joined together by a flexible peptide linker.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C63927</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P108>Single-Chain Variable Fragment</obo:NCIT_P108>
        <obo:NCIT_P207>C1883036</obo:NCIT_P207>
        <obo:NCIT_P366>Single_Chain_Variable_Fragment</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>ScFv</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Single Chain Fv</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Single Chain Variable Fragment</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Single-Chain Fv</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Single-Chain Variable Fragment</oboInOwl:hasExactSynonym>
        <rdfs:label>Single-Chain Variable Fragment</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C64995 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C64995">
        <obo:IAO_0000115>A method of drug delivery in which a usually small volume of drug is administered rapidly into a vein.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C64995</obo:NCIT_NHC0>
        <obo:NCIT_P106>Functional Concept</obo:NCIT_P106>
        <obo:NCIT_P108>Intravenous Push</obo:NCIT_P108>
        <obo:NCIT_P207>C1319196</obo:NCIT_P207>
        <obo:NCIT_P366>Intravenous_Push</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>IV Push</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Intravenous Push</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Intravenous Push Route of Administration</oboInOwl:hasExactSynonym>
        <rdfs:label>Intravenous Push</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C65216 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C65216">
        <obo:IAO_0000115>A recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon administration, adalimumab binds to TNF-alpha, thereby preventing its binding to the p55 and p75 TNF cell surface receptors and inhibiting TNF-mediated immune responses. TNF-alpha, a pro-inflammatory cytokine, is upregulated in various autoimmune diseases.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C65216</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Adalimumab</obo:NCIT_P107>
        <obo:NCIT_P108>Adalimumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1122087</obo:NCIT_P207>
        <obo:NCIT_P210>331731-18-1</obo:NCIT_P210>
        <obo:NCIT_P319>FYS6T7F842</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Adalimumab</obo:NCIT_P366>
        <obo:NCIT_P399>791684</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ADALIMUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Adalimumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>D2E7</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Humira</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LU200134</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Adalimumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C65220 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C65220">
        <obo:IAO_0000115>A recombinant dimeric fusion protein consisting of the extracellular CD2-binding domain of the human leukocyte function-associated antigen 3 (LFA-3; CD58) linked to the Fc portion of human immunoglobulin G1 (IgG1) with potential immunosuppressive activity. Alefacept binds to the CD2 receptor expressed on the majority of T lymphocytes, blocking the binding of endogenous LFA-3, located on antigen-presenting cells (APCs), to the CD2 receptor; the activation and proliferation of T lymphocytes in response to LFA-3 binding is thus inhibited. In addition, binding of the IgG1 moiety of this agent to the Fc gamma receptor on the surface of natural killer (NK)cells may bridge NK cells and target T lymphocytes, initiating NK cell-mediated apoptosis of T lymphocytes.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C15174"/>
        <obo:NCIT_NHC0>C65220</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Alefacept</obo:NCIT_P107>
        <obo:NCIT_P108>Alefacept</obo:NCIT_P108>
        <obo:NCIT_P207>C0962603</obo:NCIT_P207>
        <obo:NCIT_P210>222535-22-0</obo:NCIT_P210>
        <obo:NCIT_P319>ELK3V90G6C</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A drug that is used to treat certain skin conditions and is being studied in the treatment of cutaneous (skin-related) T-cell cancer and T-cell non-Hodgkin lymphoma. Alefacept is made by combining part of an antibody with a protein that blocks the growth some types of T cells. It is a type of fusion protein and a type of immunosuppressant.</obo:NCIT_P325>
        <obo:NCIT_P366>Alefacept</obo:NCIT_P366>
        <obo:NCIT_P375>Alefacept</obo:NCIT_P375>
        <obo:NCIT_P399>531798</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ALEFACEPT</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Alefacept</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Amevive</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LFA3TIP</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>alefacept</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Alefacept</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C66250 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C66250">
        <obo:IAO_0000115>A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_NHC0>C66250</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Ocrelizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1882138</obo:NCIT_P207>
        <obo:NCIT_P210>637334-45-3</obo:NCIT_P210>
        <obo:NCIT_P319>A10SJL62JY</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Ocrelizumab</obo:NCIT_P366>
        <obo:NCIT_P375>Ocrelizumab</obo:NCIT_P375>
        <obo:NCIT_P399>780147</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>OCRELIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ocrelizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PR070769</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PRO-70769</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PRO70769</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO4964913</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>rhuMAb 2H7</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ocrelizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C66919 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C66919">
        <obo:IAO_0000115>A cancer treatment that combines photodynamic and immunotherapy therapy to target and destroy cancer cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C66919</obo:NCIT_NHC0>
        <obo:NCIT_P106>Therapeutic or Preventive Procedure</obo:NCIT_P106>
        <obo:NCIT_P107>Photoimmunotherapy</obo:NCIT_P107>
        <obo:NCIT_P108>Photoimmunotherapy</obo:NCIT_P108>
        <obo:NCIT_P207>C1882367</obo:NCIT_P207>
        <obo:NCIT_P322>CPTAC</obo:NCIT_P322>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P366>Photoimmunotherapy</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>Photodynamic Light Therapy</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Photoimmunotherapy</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C118169"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C156952"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C158037"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C158520"/>
        <rdfs:label>Photoimmunotherapy</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C66944 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C66944">
        <obo:IAO_0000115>An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38906"/>
        <obo:NCIT_NHC0>C66944</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Brentuximab Vedotin</obo:NCIT_P107>
        <obo:NCIT_P108>Brentuximab Vedotin</obo:NCIT_P108>
        <obo:NCIT_P207>C2932409</obo:NCIT_P207>
        <obo:NCIT_P210>914088-09-8</obo:NCIT_P210>
        <obo:NCIT_P319>7XL5ISS668</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P322>PCDC</obo:NCIT_P322>
        <obo:NCIT_P350>C68H106N11O15S</obo:NCIT_P350>
        <obo:NCIT_P366>SGN-35</obo:NCIT_P366>
        <obo:NCIT_P375>Brentuximab Vedotin</obo:NCIT_P375>
        <obo:NCIT_P399>530758</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ADC SGN-35</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Adcetris</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-CD30 Antibody-Drug Conjugate SGN-35</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-CD30 Monoclonal Antibody-MMAE SGN-35</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BRENTUXIMAB VEDOTIN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Brentuximab Vedotin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SGN-35</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>cAC10-vcMMAE</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C186327"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C186328"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C186341"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Brentuximab Vedotin</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C66952 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C66952">
        <obo:IAO_0000115>A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38896"/>
        <obo:NCIT_NHC0>C66952</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Ofatumumab</obo:NCIT_P107>
        <obo:NCIT_P108>Ofatumumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1832027</obo:NCIT_P207>
        <obo:NCIT_P210>679818-59-8</obo:NCIT_P210>
        <obo:NCIT_P319>M95KG522R0</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A drug used to treat chronic lymphocytic leukemia (CLL) that has not gotten better with other chemotherapy. It is also being studied in the treatment of other types of cancer, including follicular non-Hodgkin lymphoma. Arzerra binds to CD20, a protein on the surface of normal B cells and most B-cell tumors. This may kill the cancer cells. It is a type of monoclonal antibody.</obo:NCIT_P325>
        <obo:NCIT_P366>Ofatumumab</obo:NCIT_P366>
        <obo:NCIT_P375>Ofatumumab</obo:NCIT_P375>
        <obo:NCIT_P399>530015</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Arzerra</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GSK1841157</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HuMax-CD20</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HuMax-CD20, 2F2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Kesimpta</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>OFATUMUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ofatumumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ofatumumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ofatumumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C66982 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C66982">
        <obo:IAO_0000115>A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C95308"/>
        <obo:NCIT_NHC0>C66982</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Elotuzumab</obo:NCIT_P107>
        <obo:NCIT_P108>Elotuzumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1832049</obo:NCIT_P207>
        <obo:NCIT_P210>915296-00-3</obo:NCIT_P210>
        <obo:NCIT_P319>1351PE5UGS</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody being studied in the treatment of advanced multiple myeloma. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. HuLuc63 binds to CS1, a protein that is found mainly on the surface of multiple myeloma cells.</obo:NCIT_P325>
        <obo:NCIT_P366>Anti-CS1_Monoclonal_Antibody_HuLuc63</obo:NCIT_P366>
        <obo:NCIT_P375>Elotuzumab</obo:NCIT_P375>
        <obo:NCIT_P399>532249</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>BMS-901608</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ELOTUZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Elotuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Empliciti</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HuLuc-63</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HuLuc63</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PDL-063</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PDL063</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Elotuzumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C67562 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C67562">
        <obo:IAO_0000115>A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha. Ranibizumab binds to VEGF alpha and inhibits VEGF alpha binding to its receptors, VEGFR1 and VEGFR2, thereby preventing the growth and maintenance of tumor blood vessels. The molecular weight of this agent (48 kD) is much smaller than the molecular weight of bevacizumab (MW ~149 kD), allowing complete penetration of the retina and the subretinal space following intravitreal injection. In contrast to other anti-VEGF aptamers such as pegaptanib, ranibizumab has a high specificity and affinity for all soluble human isoforms of VEGF.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C20450"/>
        <obo:NCIT_NHC0>C67562</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Ranibizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Ranibizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1566537</obo:NCIT_P207>
        <obo:NCIT_P210>347396-82-1</obo:NCIT_P210>
        <obo:NCIT_P319>ZL1R02VT79</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Ranibizumab</obo:NCIT_P366>
        <obo:NCIT_P375>Ranibizumab</obo:NCIT_P375>
        <obo:NCIT_P399>544572</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor) Fab Fragment (Human-Mouse Monoclonal rhuFab V2 Gamma1 Chain), Disulfide With Human-Mouse Monoclonal rhuFab V2 Light Chain</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Lucentis</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RANIBIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ranibizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ranibizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C68814 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C68814">
        <obo:IAO_0000115>A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94697"/>
        <obo:NCIT_NHC0>C68814</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Nivolumab</obo:NCIT_P107>
        <obo:NCIT_P108>Nivolumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3657270</obo:NCIT_P207>
        <obo:NCIT_P210>946414-94-4</obo:NCIT_P210>
        <obo:NCIT_P319>31YO63LBSN</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P322>PCDC</obo:NCIT_P322>
        <obo:NCIT_P366>Anti-PD-1_Human_Monoclonal_Antibody_MDX-1106</obo:NCIT_P366>
        <obo:NCIT_P375>Nivolumab</obo:NCIT_P375>
        <obo:NCIT_P399>539733</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>BMS-936558</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CMAB819</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MDX-1106</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>NIVO</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>NIVOLUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Nivolumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Nivolumab Biosimilar CMAB819</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ONO-4538</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Opdivo</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C186327"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C186328"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C186341"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Nivolumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C68819 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C68819">
        <obo:IAO_0000115>A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential antineoplastic activity. The Fv portion of anti-CD22 immunotoxin CAT-8015 binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumor cells. Once internalized, PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2). Anti-CD22 immunotoxin CAT-8015 exhibits a greater affinity for CD22 than its predecessor, anti-CD22 immunotoxin CAT-3888 (BL22 immunotoxin), and hence may be more effective against tumor cells expressing lower levels of CD22.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_NHC0>C68819</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Moxetumomab Pasudotox</obo:NCIT_P107>
        <obo:NCIT_P108>Moxetumomab Pasudotox</obo:NCIT_P108>
        <obo:NCIT_P207>C2717021</obo:NCIT_P207>
        <obo:NCIT_P210>1020748-57-5</obo:NCIT_P210>
        <obo:NCIT_P319>2NDX4B6N8F</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody linked to a toxic substance. It is being studied in the treatment of some types of B-cell cancer. Anti-CD22 immunotoxin CAT-8015 is made in the laboratory. It binds to CD22, a protein on the surface of normal B cells and B-cell tumors, and kills the cells.</obo:NCIT_P325>
        <obo:NCIT_P366>Anti-CD22_Immunotoxin_CAT-8015</obo:NCIT_P366>
        <obo:NCIT_P375>Moxetumomab Pasudotox</obo:NCIT_P375>
        <obo:NCIT_P399>540032</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CD22 Immunotoxin CAT-8015</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CAT-8015</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GCR-8015</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HA22</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunotoxin CAT-8015</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Lumoxiti</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MOXETUMOMAB PASUDOTOX</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Moxetumomab Pasudotox</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Moxetumomab Pasudotox-TDFK</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>anti-CD22 immunotoxin CAT-8015</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Moxetumomab Pasudotox</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C68831 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C68831">
        <obo:IAO_0000115>A humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. Efalizumab binds to CD11a, which is expressed on all leukocytes, resulting in a reduction in the cell surface expression of CD11a. In addition, this agent inhibits the binding of LFA-1 to intercellular adhesion molecule-1 (ICAM-1), resulting in the inhibition of leukocyte adherence and the suppression of cell-mediated immunity. LFA-1 binding to ICAM-1 is involved in the activation of T lymphocytes, adhesion of T lymphocytes to endothelial cells, and migration of T lymphocytes to sites of inflammation.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C68831</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Efalizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1320125</obo:NCIT_P207>
        <obo:NCIT_P210>214745-43-4</obo:NCIT_P210>
        <obo:NCIT_P319>XX2MN88N5D</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A monoclonal antibody used to treat psoriasis (a chronic skin disease). It is also being studied in the treatment of graft-versus-host disease (GVHD) of the skin after a donor stem cell transplant. Efalizumab binds to a molecule called LFA-1, and blocks the action of T cells (a type of white blood cell). It is a type of immunosuppressant.</obo:NCIT_P325>
        <obo:NCIT_P366>Efalizumab</obo:NCIT_P366>
        <obo:NCIT_P399>553413</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>EFALIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Efalizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Hu 1124</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Raptiva</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Xanelim</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>efalizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Efalizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C70741 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C70741">
        <obo:IAO_0000115>A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_NHC0>C70741</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Obinutuzumab</obo:NCIT_P107>
        <obo:NCIT_P108>Obinutuzumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2742503</obo:NCIT_P207>
        <obo:NCIT_P210>949142-50-1</obo:NCIT_P210>
        <obo:NCIT_P319>O43472U9X8</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Anti-CD20_Monoclonal_Antibody_R7159</obo:NCIT_P366>
        <obo:NCIT_P375>Obinutuzumab</obo:NCIT_P375>
        <obo:NCIT_P399>570643</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Afutuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-CD20 Monoclonal Antibody R7159</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GA-101</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GA101</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Gazyva</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>OBINUTUZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Obinutuzumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>R7159</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO 5072759</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO-5072759</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO5072759</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>huMAB(CD20)</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Obinutuzumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C70792 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C70792">
        <obo:IAO_0000115>A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C28496"/>
        <obo:NCIT_NHC0>C70792</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Ramucirumab</obo:NCIT_P107>
        <obo:NCIT_P108>Ramucirumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2742502</obo:NCIT_P207>
        <obo:NCIT_P210>947687-13-0</obo:NCIT_P210>
        <obo:NCIT_P319>D99YVK4L0X</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A substance being studied in the treatment of breast cancer that has come back. It binds to receptors for a protein called vascular endothelial growth factor (VEGF). This keeps VEGF from binding to the receptors and may stop the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.</obo:NCIT_P325>
        <obo:NCIT_P366>Anti-VEGFR-2_Fully_Human_Monoclonal_Antibody_IMC-1121B</obo:NCIT_P366>
        <obo:NCIT_P375>Ramucirumab</obo:NCIT_P375>
        <obo:NCIT_P399>570535</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cyramza</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IMC-1121B</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LY3009806</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody HGS-ETR2</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RAMUCIRUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ramucirumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>anti-VEGFR-2 fully human monoclonal antibody IMC-1121B</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ramucirumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ramucirumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C71542 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C71542">
        <obo:IAO_0000115>A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17279"/>
        <obo:NCIT_NHC0>C71542</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Inotuzumab Ozogamicin</obo:NCIT_P107>
        <obo:NCIT_P108>Inotuzumab Ozogamicin</obo:NCIT_P108>
        <obo:NCIT_P207>C1567130</obo:NCIT_P207>
        <obo:NCIT_P210>635715-01-4</obo:NCIT_P210>
        <obo:NCIT_P319>P93RUU11P7</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P350>C73H96IN6O25S3</obo:NCIT_P350>
        <obo:NCIT_P366>Anti-CD22-CalichDMH_Conjugate</obo:NCIT_P366>
        <obo:NCIT_P375>Inotuzumab Ozogamicin</obo:NCIT_P375>
        <obo:NCIT_P399>352004</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Besponsa</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CMC-544</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>INOTUZUMAB OZOGAMICIN</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Inotuzumab Ozogamicin</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>WAY-207294</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Way 207294</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Inotuzumab Ozogamicin</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C74007 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C74007">
        <obo:IAO_0000115>A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C84323"/>
        <obo:NCIT_NHC0>C74007</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Daratumumab</obo:NCIT_P107>
        <obo:NCIT_P108>Daratumumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2346802</obo:NCIT_P207>
        <obo:NCIT_P210>945721-28-8</obo:NCIT_P210>
        <obo:NCIT_P319>4Z63YK6E0E</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Anti-CD38_Monoclonal_Antibody</obo:NCIT_P366>
        <obo:NCIT_P375>Daratumumab</obo:NCIT_P375>
        <obo:NCIT_P399>583564</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CD38 Monoclonal Antibody</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>DARATUMUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Daratumumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Darzalex</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>HuMax-CD38</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>JNJ-54767414</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Daratumumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C76128 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C76128">
        <obo:IAO_0000115>A Fab fragment of the chimeric monoclonal antibody 7E3 and inhibitor of the glycoprotein (GP) IIb/IIIa receptor, that blocks platelet aggregation. Abciximab binds to the GP IIb/IIIa receptor on the platelet membrane, which inhibits the binding of fibrinogen to the GP IIb/IIIa receptor. This prevents both platelet aggregation and thrombus formation.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C76128</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Abciximab</obo:NCIT_P108>
        <obo:NCIT_P207>C0288672</obo:NCIT_P207>
        <obo:NCIT_P210>143653-53-6</obo:NCIT_P210>
        <obo:NCIT_P319>X85G7936GV</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Abciximab</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>ABCIXIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Abciximab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Chimeric 7E3 Fab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MoAb 7E3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ReoPro</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Abciximab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C77862 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C77862">
        <obo:IAO_0000115>A humanized recombinant IgG4 monoclonal antibody directed against the alpha4 subunit of the integrins alpha4beta1and alpha4beta7 with immunomodulating, anti-inflammatory, and potential antineoplastic activities.  Natalizumab binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins expressed on the surface of all leukocytes except neutrophils, inhibiting the alpha4-mediated adhesion of leukocytes to counter-receptor(s) such as vascular cell adhesion molecule-1 (VCAM-1); natalizumab-mediated disruption of VCAM-1 binding by these integrins may prevent the transmigration of leukocytes across the endothelium into inflamed parenchymal tissue.  Integrins are cellular adhesion molecules (CAMs) that are upregulated in various types of cancer and some autoimmune diseases; alpha4beta1 integrin (VLA4) has been implicated in the survival of myeloma cells, possibly by mediating their adhesion to stromal cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_NHC0>C77862</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Natalizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Natalizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1172734</obo:NCIT_P207>
        <obo:NCIT_P210>189261-10-7</obo:NCIT_P210>
        <obo:NCIT_P319>3JB47N2Q2P</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Natalizumab</obo:NCIT_P366>
        <obo:NCIT_P375>Natalizumab</obo:NCIT_P375>
        <obo:NCIT_P399>596513</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>AN100226</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Antegren</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-VLA4</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-alph4 Integrin Monoclonal Antibody AN100226</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>NATALIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Natalizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tysabri</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Natalizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C79825 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C79825">
        <obo:IAO_0000115>A fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody IMC-3G3 selectively binds to PDGFR alpha, .blocking the binding of its ligand, PDGF; signal transduction downstream of PDGFR through the MAPK and PI3K pathways is inhibited, which may result in inhibition of angiogenesis and tumor cell proliferation. Overexpressed by various cancer cell types, PDGFR is a transmembrane protein tyrosine kinase receptor, consisting of isoforms A and B that is important in regulating cellular growth and differentiation and angiogenesis.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_NHC0>C79825</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Olaratumab</obo:NCIT_P107>
        <obo:NCIT_P108>Olaratumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2703171</obo:NCIT_P207>
        <obo:NCIT_P210>1024603-93-7</obo:NCIT_P210>
        <obo:NCIT_P319>TT6HN20MVF</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A substance being studied in the treatment of glioblastoma (a type of brain tumor) that has come back. It binds to receptors for a protein called platelet-derived growth factor (PDGF). This keeps PDGF from binding to the cells. This may stop the growth of cancer cells and blood vessels that have the receptors for PDGF. It is a type of monoclonal antibody.</obo:NCIT_P325>
        <obo:NCIT_P366>Anti-PDGFR_alpha_Monoclonal_Antibody_IMC-3G3</obo:NCIT_P366>
        <obo:NCIT_P375>Olaratumab</obo:NCIT_P375>
        <obo:NCIT_P399>626630</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-PDGFR alpha Monoclonal Antibody IMC-3G3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Anti-Platelet-Derived Growth Factor Receptor alpha Monoclonal Antibody IMC-3G3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IMC-3G3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Lartruvo</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>OLARATUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Olaratumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>anti-PDGFR alpha monoclonal antibody IMC-3G3</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>anti-platelet-derived growth factor receptor alpha monoclonal antibody IMC-3G3</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Olaratumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C80255 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C80255">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17489"/>
        <obo:NCIT_NHC0>C80255</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Belatacept</obo:NCIT_P108>
        <obo:NCIT_P207>C1619962</obo:NCIT_P207>
        <obo:NCIT_P210>706808-37-9</obo:NCIT_P210>
        <obo:NCIT_P319>E3B2GI648A</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Belatacept</obo:NCIT_P366>
        <oboInOwl:hasExactSynonym>BELATACEPT</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BMS-224818</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Belatacept</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CD152 Antigen</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cytotoxic T-lymphocyte Antigen 4</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LEA 29Y</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LEA29Y</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Nulojix</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Belatacept</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C80971 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C80971">
        <obo:IAO_0000115>A recombinant monoclonal antibody targeting human interleukin-1 beta (IL-1b), with anti-inflammatory and immunomodulating activities. Canakinumab binds IL-1b and prevents the binding of IL-1b to the IL-1 receptor and inhibits IL-1b-mediated signaling. This may suppress inflammatory responses mediated by IL-1b. IL-1b, a proinflammatory cytokine, plays a key role in inflammation.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C20522"/>
        <obo:NCIT_NHC0>C80971</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Canakinumab</obo:NCIT_P107>
        <obo:NCIT_P108>Canakinumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2718773</obo:NCIT_P207>
        <obo:NCIT_P210>914613-48-2</obo:NCIT_P210>
        <obo:NCIT_P319>37CQ2C7X93</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Canakinumab</obo:NCIT_P366>
        <obo:NCIT_P399>795723</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ACZ885</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CANAKINUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Canakinumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ilaris</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Canakinumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C80972 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C80972">
        <obo:IAO_0000115>A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and conjugated to polyethylene glycol (PEG), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha and prevents the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis. Pegylation of certolizumab allows for an improved pharmacokinetic profile.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C80972</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Certolizumab Pegol</obo:NCIT_P108>
        <obo:NCIT_P207>C1872109</obo:NCIT_P207>
        <obo:NCIT_P210>428863-50-7</obo:NCIT_P210>
        <obo:NCIT_P319>UMD07X179E</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P350>C19H30N5O8S(C2H4O)n(C2H4O)n</obo:NCIT_P350>
        <obo:NCIT_P366>Certolizumab_Pegol</obo:NCIT_P366>
        <obo:NCIT_P368>CHEBI:63585</obo:NCIT_P368>
        <obo:NCIT_P399>791843</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>CDP 870</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CDP870</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CERTOLIZUMAB PEGOL</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CZP</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Certolizumab Pegol</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Cimzia</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PHA-738144</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Certolizumab Pegol</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C82492 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C82492">
        <obo:IAO_0000115>An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17319"/>
        <obo:NCIT_NHC0>C82492</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Trastuzumab Emtansine</obo:NCIT_P107>
        <obo:NCIT_P108>Trastuzumab Emtansine</obo:NCIT_P108>
        <obo:NCIT_P207>C2935436</obo:NCIT_P207>
        <obo:NCIT_P210>1018448-65-1</obo:NCIT_P210>
        <obo:NCIT_P319>SE2KH7T06F</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P350>C47H63ClN5O13S</obo:NCIT_P350>
        <obo:NCIT_P366>Trastuzumab-MCC-DM1_Conjugate</obo:NCIT_P366>
        <obo:NCIT_P375>Trastuzumab Emtansine</obo:NCIT_P375>
        <obo:NCIT_P399>564399</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>ADO-Trastuzumab Emtansine</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ado Trastuzumab Emtansine</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human p185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide with N2&apos;-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2&apos;-deacetylMaytansine</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Kadcyla</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PRO132365</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO5304020</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>T-DM1</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TRASTUZUMAB EMTANSINE</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab Emtansine</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab-DM1</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab-MCC-DM1</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab-MCC-DM1 Antibody-Drug Conjugate</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Trastuzumab-MCC-DM1 Immunoconjugate</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Trastuzumab Emtansine</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C84137 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C84137">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C84137</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Rilonacept</obo:NCIT_P108>
        <obo:NCIT_P207>C2343589</obo:NCIT_P207>
        <obo:NCIT_P210>501081-76-1</obo:NCIT_P210>
        <obo:NCIT_P319>8K80YB5GMG</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>Arcalyst</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IL-1 Trap</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Interleukin-1 Trap</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RILONACEPT</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Rilonacept</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Rilonacept</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C84217 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C84217">
        <obo:IAO_0000115>A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C156002"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38921"/>
        <obo:NCIT_NHC0>C84217</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Tocilizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Tocilizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1609165</obo:NCIT_P207>
        <obo:NCIT_P210>375823-41-9</obo:NCIT_P210>
        <obo:NCIT_P319>I031V2H011</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P368>CHEBI:64360</obo:NCIT_P368>
        <obo:NCIT_P375>Tocilizumab</obo:NCIT_P375>
        <obo:NCIT_P399>713832</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Actemra</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MRA</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>R-1569</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RoActemra</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TOCILIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tocilizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tocilizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C84237 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C84237">
        <obo:IAO_0000115>An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with immunomodulating activity. Upon administration, ustekinumab binds to the p40 subunit of IL-12 and IL-23, blocking the binding of IL-12 and IL-23 to their interleukin receptors. This inhibits IL-12- and IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent graft versus host disease (GVHD). IL-12 and IL-23, cytokines that play a key role in the regulation of the immune system, are upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C28509"/>
        <obo:NCIT_NHC0>C84237</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Ustekinumab</obo:NCIT_P107>
        <obo:NCIT_P108>Ustekinumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1608841</obo:NCIT_P207>
        <obo:NCIT_P210>815610-63-0</obo:NCIT_P210>
        <obo:NCIT_P319>FU77B4U5Z0</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>747205</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>CNTO 1275</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>CNTO1275</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human Interleukin-12 Subunit beta (IL-12B, CLMF p40, NKSF2)) (Human Monoclonal CNTO 1275 gamma1-chain), Disulfide with Human Monoclonal CNTO 1275 kappa-chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Stelara</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>USTEKINUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ustekinumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ustekinumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C87766 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C87766">
        <obo:IAO_0000115>A human monoclonal antibody directed against the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-a) with immunosuppressive activity. Golimumab binds to TNF-a, thereby preventing TNF-a-mediated immune responses. TNF-a production is dysregulated in various auto-immune diseases and in cancer.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C87766</obo:NCIT_NHC0>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Golimumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2353893</obo:NCIT_P207>
        <obo:NCIT_P210>476181-74-5</obo:NCIT_P210>
        <obo:NCIT_P319>91X1KLU43E</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>791699</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>CNTO 148</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>GOLIMUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Golimumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Alpha) (Human Monoclonal CNTO 148 Gamma-1-Chain), Disulfide with Human Monoclonal CNTO 148 Kappa-Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Golimumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C87767 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C87767">
        <obo:IAO_0000115>A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. Lebrikizumab binds to IL-13 and inhibits IL-13-mediated pathways. IL-13, a cytokine mainly secreted by type 2 helper T cells, plays a key role in the induction of allergic inflammation.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C20515"/>
        <obo:NCIT_NHC0>C87767</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Lebrikizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Lebrikizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2981360</obo:NCIT_P207>
        <obo:NCIT_P210>953400-68-5</obo:NCIT_P210>
        <obo:NCIT_P319>U9JLP7V031</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P366>Monoclonal_Antibody_TNX-650</obo:NCIT_P366>
        <obo:NCIT_P375>Anti-IL-13 Humanized Monoclonal Antibody TNX-650</obo:NCIT_P375>
        <obo:NCIT_P399>539362</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-IL-13 Humanized Monoclonal Antibody TNX-650</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G4, Anti-(Human Interleukin 13) (Human-Mouse Monoclonal MILR1444a Gamma-4-Chain), Disulfide with Human-Mouse Monoclonal MILR1444a Kappa-Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LEBRIKIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Lebrikizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MILR1444A</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal Antibody TNX-650</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>PRO301444</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TNX-650</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Lebrikizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C88281 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C88281">
        <obo:IAO_0000115>A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17068"/>
        <obo:NCIT_NHC0>C88281</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Necitumumab</obo:NCIT_P107>
        <obo:NCIT_P108>Necitumumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2352806</obo:NCIT_P207>
        <obo:NCIT_P210>906805-06-9</obo:NCIT_P210>
        <obo:NCIT_P319>2BT4C47RUI</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Necitumumab</obo:NCIT_P375>
        <obo:NCIT_P399>656651</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-Epidermal Growth Factor Receptor Monoclonal Antibody IMC-11F8</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>IMC-11F8</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor (Receptor Tyrosine-Protein Kinase ErbB-1, EC 2.7.10.1)); Human Monoclonal IMC-11F8 Gamma1 Heavy Chain (224-214&apos;)-Disulfide with Human Monoclonal IMC-11F8 Kappa Light Chain, Dimer (230- 230&apos;&apos;:233-233&apos;&apos;)-Bisdisulfide</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>NECITUMUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Necitumumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Portrazza</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Necitumumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C88283 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C88283">
        <obo:IAO_0000115>A humanized immunoglobulin IgG1 kappa monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential immunostimulating and antineoplastic activities. Inebilizumab binds to CD19, which may result in a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cellular cytotoxicity (ADCC) to CD19-expressing B-cells. The Fc portion of inebilizumab does not contain a fucose sugar moiety, which may contribute to its enhanced ADCC activity. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38894"/>
        <obo:NCIT_NHC0>C88283</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Inebilizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Inebilizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2981806</obo:NCIT_P207>
        <obo:NCIT_P210>1299440-37-1</obo:NCIT_P210>
        <obo:NCIT_P319>74T7185BMM</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-CD19 Monoclonal Antibody MEDI-551</obo:NCIT_P375>
        <obo:NCIT_P375>Inebilizumab</obo:NCIT_P375>
        <obo:NCIT_P399>656851</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>INEBILIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Inebilizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MEDI-551</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Inebilizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C88594 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C88594">
        <obo:IAO_0000115>An afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra), with potential anti-asthmatic activity. Upon administration, benralizumab binds to IL-5Ra and elicits an antibody-directed cell cytotoxicity (ADCC) against IL-5Ra-expressing cells. This induces apoptosis in IL-5Ra-expressing cells and may reduce asthmatic episodes. IL-5Ra, expressed on both eosinophils and basophils, plays a key role in asthma.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C26269"/>
        <obo:NCIT_NHC0>C88594</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Benralizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Benralizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2982078</obo:NCIT_P207>
        <obo:NCIT_P210>1044511-01-4</obo:NCIT_P210>
        <obo:NCIT_P319>71492GE1FX</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P399>794137</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-CD125 Humanized Monoclonal Antibody, IgG1-kappa</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BENRALIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>BIW-8405</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Benralizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>KHK-4563</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MEDI-563</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Benralizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C88612 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C88612">
        <obo:IAO_0000115>A humanized monoclonal antibody against CD4, with anti-human immunodeficiency virus (HIV) activity. Ibalizumab binds to CD4, the primary receptor for HIV, thereby inhibiting HIV entry into CD4-positive T-cells. This leads to a reduction in viral load.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C88612</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Ibalizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1434792</obo:NCIT_P207>
        <obo:NCIT_P210>680188-33-4</obo:NCIT_P210>
        <obo:NCIT_P319>LT369U66CE</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>IBALIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ibalizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G4, Anti-(Human CD4 (Antigen)) (Human-Mouse Monoclonal 5A8 Gamma-4-Chain), Disulfide with Human-Mouse Monoclonal 5A8 Kappa-Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TNX-355</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ibalizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C88647 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C88647">
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C88647</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Teplizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2743673</obo:NCIT_P207>
        <obo:NCIT_P210>876387-05-2</obo:NCIT_P210>
        <obo:NCIT_P319>S4M959U2IJ</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human CD3 (Antigen)Epsilon-Chain)(Human-Mouse Monoclonal MGA031 Heavy Chain), Disulfide with Human-Mouse Monoclonal MGA031 Light-Chain Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MGA031</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TEPLIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Teplizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Teplizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C90578 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C90578">
        <obo:IAO_0000115>A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C84323"/>
        <obo:NCIT_NHC0>C90578</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Isatuximab</obo:NCIT_P107>
        <obo:NCIT_P108>Isatuximab</obo:NCIT_P108>
        <obo:NCIT_P207>C2983777</obo:NCIT_P207>
        <obo:NCIT_P210>1461640-62-9</obo:NCIT_P210>
        <obo:NCIT_P319>R30772KCU0</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Isatuximab</obo:NCIT_P375>
        <obo:NCIT_P399>668181</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Hu 38SB19</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ISATUXIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human CD38 Antigen) (Human-mus musculus Monoclonal HU38SB19 Heavy Chain), Disulfide with Human-mus musculus Monoclonal HU38SB19 Light Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Isatuximab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Isatuximab-irfc</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SAR 650984</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>SAR650984</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Sarclisa</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Isatuximab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C91078 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C91078">
        <obo:IAO_0000115>A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38896"/>
        <obo:NCIT_NHC0>C91078</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Ublituximab</obo:NCIT_P107>
        <obo:NCIT_P108>Ublituximab</obo:NCIT_P108>
        <obo:NCIT_P207>C2934225</obo:NCIT_P207>
        <obo:NCIT_P210>1174014-05-1</obo:NCIT_P210>
        <obo:NCIT_P319>U59UGK3IPC</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Ublituximab</obo:NCIT_P375>
        <obo:NCIT_P399>670500</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>LFB-R603</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TG-1101</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TG-20</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TGTX-1101</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>UBLITUXIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Ublituximab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Ublituximab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C91385 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C91385">
        <obo:IAO_0000115>A fully human IgG1 monoclonal antibody directed against B-Lymphocyte stimulator protein (BlyS or TNFSF13B) with potential immunomodulating activity. Belimumab specifically recognizes and inhibits the biological activity of BlyS, thereby preventing the binding of BlyS to B-lymphocytes. This inhibits the maturation of B-lymphocytes and may induce apoptosis in B-lymphocytes. In addition, it may decrease B-lymphocyte proliferation and/or survival. BlyS, a member of TNF family supporting B-lymphocyte maturation and survival, has been implicated in the pathogenesis of autoimmune diseases and B-lymphocyte malignancies.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C94789"/>
        <obo:NCIT_NHC0>C91385</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Belimumab</obo:NCIT_P107>
        <obo:NCIT_P108>Belimumab</obo:NCIT_P108>
        <obo:NCIT_P207>C1723401</obo:NCIT_P207>
        <obo:NCIT_P210>356547-88-1</obo:NCIT_P210>
        <obo:NCIT_P319>73B0K5S26A</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Belimumab</obo:NCIT_P375>
        <obo:NCIT_P399>680522</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>BELIMUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Belimumab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Benlysta</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, anti-(Human Cytokine BAFF) (Human Monoclonal LymphoStat-B Heavy Chain), Disulfide with Human Monoclonal LymphoStat-B lambda-chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LymphoStat-B</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Belimumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C91733 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C91733">
        <obo:IAO_0000115>A Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. After binding to HER2 on the tumor cell surface, margetuximab may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells overexpressing HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Compared to other anti-HER2 monoclonal antibodies, the Fc domain of MGAH22 is optimized with increased binding to the activating Fcgamma receptor IIIA (CD16A), expressed on cells such as natural killer (NK) cells and macrophages, thereby mediating an enhanced ADCC; the Fc domain also shows decreased binding to the inhibitory Fcgamma receptor IIB (CD32B).</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17319"/>
        <obo:NCIT_NHC0>C91733</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Margetuximab</obo:NCIT_P107>
        <obo:NCIT_P108>Margetuximab</obo:NCIT_P108>
        <obo:NCIT_P208>CL421637</obo:NCIT_P208>
        <obo:NCIT_P210>1350624-75-7</obo:NCIT_P210>
        <obo:NCIT_P319>K911R84KEW</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Margetuximab</obo:NCIT_P375>
        <obo:NCIT_P399>681010</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(human Neu (Receptor)) (Human-Mus musculus Monoclonal MGAH22 Clone ch4D5 Heavy Chain), Disulfide with Human-Mus musculus Monoclonal MGAH22 Clone ch4D5 Light Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MARGETUXIMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MGAH-22</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MGAH22</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Margenza</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Margetuximab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Margetuximab-cmkb</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Margetuximab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C94208 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C94208">
        <obo:IAO_0000115>A fusion protein containing a modified form of human T-cell receptor (TCR) specific for the gp100 antigen and fused to an anti-CD3 single-chain antibody fragment, with potential antineoplastic activity. Upon direct intratumoral administration of tebentafusp into the melanoma lesion, the TCR moiety of this agent targets and binds to the tumor associated antigen (TAA) gp100 presented on the melanoma tumor cell; the anti-CD3 fragment moiety binds to CD3- expressing T lymphocytes, thereby selectively cross-linking tumor cells and T-lymphocytes. This may lead to the recruitment of cytotoxic T lymphocytes (CTL) to the T lymphocyte/tumor cell aggregates and result in CTL-mediated death of gp100-expressing melanoma cancer cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C41037"/>
        <obo:NCIT_NHC0>C94208</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Tebentafusp</obo:NCIT_P107>
        <obo:NCIT_P108>Tebentafusp</obo:NCIT_P108>
        <obo:NCIT_P208>CL426021</obo:NCIT_P208>
        <obo:NCIT_P210>1874157-95-5</obo:NCIT_P210>
        <obo:NCIT_P319>N658GY6L3E</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100</obo:NCIT_P375>
        <obo:NCIT_P375>Tebentafusp</obo:NCIT_P375>
        <obo:NCIT_P399>686537</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>IMCgp100</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>ImmTAC-gp100</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Kimmtrak</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TEBENTAFUSP</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tebentafusp</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tebentafusp-tebn</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tebentafusp</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C95024 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C95024">
        <obo:IAO_0000115>An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_NHC0>C95024</obo:NCIT_NHC0>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Racotumomab</obo:NCIT_P108>
        <obo:NCIT_P207>C2986854</obo:NCIT_P207>
        <obo:NCIT_P210>946832-34-4</obo:NCIT_P210>
        <obo:NCIT_P319>52G405U1E5</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Racotumomab</obo:NCIT_P375>
        <obo:NCIT_P399>689646</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-P3 Antibody Idiotype Monoclonal Antibody 1E10</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MoAb 1E10</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RACOTUMOMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Racotumomab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Racotumomab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C95768 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C95768">
        <obo:IAO_0000115>An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C38894"/>
        <obo:NCIT_NHC0>C95768</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Tafasitamab</obo:NCIT_P107>
        <obo:NCIT_P108>Tafasitamab</obo:NCIT_P108>
        <obo:NCIT_P208>CL421662</obo:NCIT_P208>
        <obo:NCIT_P210>1422527-84-1</obo:NCIT_P210>
        <obo:NCIT_P319>QQA9MLH692</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Anti-CD19 Monoclonal Antibody XmAb5574</obo:NCIT_P375>
        <obo:NCIT_P375>Tafasitamab</obo:NCIT_P375>
        <obo:NCIT_P399>682091</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MOR-00208</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MOR00208</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MOR208</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Monjuvi</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TAFASITAMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tafasitamab</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Tafasitamab-cxix</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>XmAb5574</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Tafasitamab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C95787 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C95787">
        <obo:IAO_0000115>A humanized IgG1 monoclonal antibody targeting the T-cell differentiation antigen CD6, with immunmodulating activity. Itolizumab binds to CD6, downregulates the activation and differentiation of T cells, prevents CD6-mediated activation pathways and reduces the synthesis of pro-inflammatory cytokines. CD6, a co-stimulatory molecule predominantly expressed on lymphocytes, is involved in the adhesion and maturation of T cells.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_NHC0>C95787</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P108>Itolizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2987424</obo:NCIT_P207>
        <obo:NCIT_P210>1116433-11-4</obo:NCIT_P210>
        <obo:NCIT_P319>XQQ2RHV14N</obo:NCIT_P319>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <oboInOwl:hasExactSynonym>ITOLIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Itolizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173381"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C173383"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Itolizumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C95797 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C95797">
        <obo:IAO_0000115>A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Teprotumumab binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the activation of PI3K/AKT signal transduction; downregulation of the PI3K/AKT survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C17531"/>
        <obo:NCIT_NHC0>C95797</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Teprotumumab</obo:NCIT_P107>
        <obo:NCIT_P108>Teprotumumab</obo:NCIT_P108>
        <obo:NCIT_P207>C3181764</obo:NCIT_P207>
        <obo:NCIT_P210>89957-37-9</obo:NCIT_P210>
        <obo:NCIT_P319>Y64GQ0KC0A</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P325>A human monoclonal antibody being studied in the treatment of several types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. R1507 blocks the action of a protein needed for cell growth and may kill cancer cells. It is a type of insulin-like growth factor-1 receptor (IGF-1R) inhibitor.</obo:NCIT_P325>
        <obo:NCIT_P375>Teprotumumab</obo:NCIT_P375>
        <obo:NCIT_P399>557569</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Anti-IGF-1R Monoclonal Antibody R1507</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human Insulin-like Growth Factor I Receptor)(Human Monoclonal Heavy Chain), Disulfide with Human Monoclonal Light Chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>R1507</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RG1507</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RO4858696-000</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>RV001 Monoclonal</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>TEPROTUMUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Teprotumumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Teprotumumab</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/NCIT_C95798 -->

    <owl:Class rdf:about="http://purl.obolibrary.org/obo/NCIT_C95798">
        <obo:IAO_0000115>A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer&apos;s patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.</obo:IAO_0000115>
        <obo:IAO_0000412 rdf:resource="http://purl.obolibrary.org/obo/ncit.owl"/>
        <obo:NCIT_A32 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C1909"/>
        <obo:NCIT_A7 rdf:resource="http://purl.obolibrary.org/obo/NCIT_C121993"/>
        <obo:NCIT_NHC0>C95798</obo:NCIT_NHC0>
        <obo:NCIT_P106>Amino Acid, Peptide, or Protein</obo:NCIT_P106>
        <obo:NCIT_P106>Immunologic Factor</obo:NCIT_P106>
        <obo:NCIT_P106>Pharmacologic Substance</obo:NCIT_P106>
        <obo:NCIT_P107>Vedolizumab</obo:NCIT_P107>
        <obo:NCIT_P108>Vedolizumab</obo:NCIT_P108>
        <obo:NCIT_P207>C2742797</obo:NCIT_P207>
        <obo:NCIT_P210>943609-66-3</obo:NCIT_P210>
        <obo:NCIT_P319>9RV78Q2002</obo:NCIT_P319>
        <obo:NCIT_P322>CTRP</obo:NCIT_P322>
        <obo:NCIT_P322>FDA</obo:NCIT_P322>
        <obo:NCIT_P375>Vedolizumab</obo:NCIT_P375>
        <obo:NCIT_P399>781604</obo:NCIT_P399>
        <oboInOwl:hasExactSynonym>Entyvio</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, Anti-(Human Integrin LPAM-1 (Lymphocyte Peyer&apos;s Patch Adhesion Molecule 1)) (Human-Mus musculus Heavy Chain), Disulfide with Human-Mus musculus kappa-chain, Dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Immunoglobulin G1, anti-(human integrin LPAM-1 (lymphocyte Peyer&apos;s patch adhesion molecule 1)) (human-Mus musculus heavy chain), disulfide with human-Mus musculus kappa-chain, dimer</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LDP 02</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LDP-02</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>LDP02</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MLN0002</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>MLN02</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>VEDOLIZUMAB</oboInOwl:hasExactSynonym>
        <oboInOwl:hasExactSynonym>Vedolizumab</oboInOwl:hasExactSynonym>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C128784"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157712"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C176424"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C177537"/>
        <oboInOwl:inSubset rdf:resource="http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923"/>
        <rdfs:label>Vedolizumab</rdfs:label>
    </owl:Class>
</rdf:RDF>



<!-- Generated by the OWL API (version 4.5.25.2023-02-15T19:15:49Z) https://github.com/owlcs/owlapi -->

